US20160024011A1 - Multi-API Loading Prodrugs - Google Patents

Multi-API Loading Prodrugs Download PDF

Info

Publication number
US20160024011A1
US20160024011A1 US14/702,967 US201514702967A US2016024011A1 US 20160024011 A1 US20160024011 A1 US 20160024011A1 US 201514702967 A US201514702967 A US 201514702967A US 2016024011 A1 US2016024011 A1 US 2016024011A1
Authority
US
United States
Prior art keywords
optionally substituted
prodrug
api
formula
parent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/702,967
Inventor
Tarek A. Zeidan
Laura Cook Blumberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Pharma Ireland Ltd
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Priority to US14/702,967 priority Critical patent/US20160024011A1/en
Publication of US20160024011A1 publication Critical patent/US20160024011A1/en
Priority to US15/864,305 priority patent/US10584099B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to prodrugs that can be linked to multiple drug molecules.
  • Drug delivery systems are often critical for the safe and effective administration of a biologically active agent. Perhaps the importance of these systems is best realized when patient compliance and consistent dosing are taken under consideration. For instance, reducing the dosing requirement for a drug from four-times-a-day to a single dose per day would have significant value in terms of ensuring patient compliance and optimizing therapy. Many of the currently administered prodrugs and formulations require large amounts of drug/excipient/prodrug mixtures for administration.
  • a wide range of pharmaceutical formulations provide sustained release through microencapsulation of the active agent in amides of dicarboxylic acids, modified amino acids or thermally condensed amino acids.
  • Slow release rendering additives can also be intermixed with a large array of active agents in tablet formulations. Many of these formulations, however, deliver relatively low amounts of parent drugs in comparison with the overall weight of the formulations.
  • microencapsulation and enteric coating technologies impart enhanced stability and time-release properties to active agent substances these technologies suffer from several shortcomings. Incorporation of the active agent is often dependent on diffusion into the microencapsulating matrix, which may not be quantitative and may complicate dosage reproducibility. In addition, encapsulated drugs rely on diffusion out of the matrix or degradation of the matrix, or both, which is highly dependent on the chemical properties and water solubility of the active agent. Conversely, water-soluble microspheres swell by an infinite degree and, unfortunately, may release the active agent in bursts with limited active agent available for sustained release. Furthermore, in some technologies, control of the degradation process required for active agent release is unreliable. For example, because an enterically coated active agent depends on pH to release the active agent and pH and residence time varies, the release rate is difficult to control.
  • the present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself.
  • the compounds suitable for use in the methods of the invention are derivatives of heteroaryl, lactam-, amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, N-acylaniline-, and cyclic amide-, and tertiary amine containing parent drugs that are substituted at a nitrogen or oxygen atom with a labile aldehyde-linked prodrug moieties.
  • the prodrug moieties are hydrophobic and reduce the polarity and solubility of the parent drug under physiological conditions.
  • the invention provides a prodrug compound of Formula I, IA or IB:
  • each API is the same biologically active moiety.
  • the API groups represent two or more different biologically active moieties.
  • the invention further provides a method for sustained delivery of a parent drug by the administration of a conjugate of the parent drug with a labile moiety, wherein the conjugate is represented by Formula I, IA or IB.
  • the present provides a method for attaching multiple parent drugs (biologically active moieties) to a carrier moiety resulting in a conjugate that can undergo spontaneous or enzyme assisted cleavage in physiological conditions to release the parent drug.
  • the release of the parent drug is sustained release.
  • the sustained release is accomplished by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself.
  • the prodrug moieties are hydrophobic and reduce the polarity and solubility of the parent drug under physiological conditions.
  • One of the challenges for delivering a prodrug is the high amount of prodrug needed to be dosed compared to the parent drug due to the higher molecular weight of the prodrug compared to the parent drug.
  • Having a multivalent carrier moiety that can link two or more parent drug moieties can decrease the dose load.
  • such a multivalent carrier can link two different APIs.
  • molecules of Aripiprazole and Dehydroaripiprazole can be linked to the same carrier moiety.
  • two molecules can be linked to the same carrier so that they will be released through different mechanisms.
  • a quaternary ammonium prodrug can easily hydrolyze in physiological conditions.
  • a parent drug linked through another functional group that relies on enzymatic action might release more slowly.
  • two parent drugs can be linked to a single carrier moiety, the first via a quaternary ammonium group on one end and the second through a labile functional group. This allows one to tailor the release of the two parent drugs, with faster delivery of one parent drug compared to the other based on chemical reactivity and/or enzymatic activity.
  • the invention provides a prodrug compound of Formula I, IA or IB:
  • the invention further relates to prodrugs of secondary amine containing drugs of Formula LI:
  • the invention further provides a method for sustained delivery of a parent drug by the administration of a multivalent conjugate of the parent drug with a labile moiety, wherein the conjugate is represented by Formula I, IA, IB or LI.
  • C1 is selected from optionally substituted aliphatic, aryl or substituted aryl. In some embodiments, C1 is selected from optionally substituted C 1 -C 30 alkyl, optionally substituted C 2 -C 30 alkenyl, optionally substituted C 1 -C 30 alkynyl, optionally substituted C 1 -C 30 aryl.
  • C1 is selected from optionally substituted bicyclic heteroaryl group selected from benzofuran, benzothiophene, indole, benzimidazole, indazole, benzotriazole, pyrrolo[2,3]pyridine, imidazopyridine, pyrazolopyridine, isoindole, quinoline, isoquinoline, quinazoline, quinoxaline, phthalazine, indazole, purine, indolizine, indole, indoline, isoindoline, benzofuran and chromene.
  • C1 is a polyethyleneglycol group having a molecular weight of about 400 dalton to about 100,000 dalton.
  • C1 is selected from:
  • c is selected from 0, 1, 2, 3 and 4; g is an integer from 1 to about 1,000; each b and d is independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13; s and t are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30; each R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 is independently selected from absent, hydrogen, halogen, —OR 20 , —SR 20 , —NR 20 R 21 , —C(O)R 20 , —C(O)OR 20 , —C(O)NR 20 R 21 , —N(R 20 )C(O)R 21 , —CF 3 , —CN, —NO 2 , —N 3 , acyl, optionally substituted alkoxy, optionally substituted alkylamino, optionally substituted dialkylamino
  • C1 is a dendrimer
  • the invention relates to a prodrug conjugate of Formula II:
  • the invention relates to a prodrug conjugate having the formula:
  • the invention relates to a prodrug conjugate having the formula:
  • the invention relates to a prodrug conjugate having the formula:
  • n is an integer between about 1 and about 50; each R 10 and R 11 is independently selected from absent, hydrogen, halogen, —OR 20 , —SR 20 , —NR 20 R 21 , —C(O)R 20 , —C(O)OR 20 , —C(O)NR 20 R 21 , —N(R 20 )C(O)R 21 , —CF 3 , —CN, —NO 2 , —N 3 , acyl, optionally substituted alkoxy, optionally substituted alkylamino, optionally substituted dialkylamino, optionally substituted alkylthio, optionally substituted alkylsulfonyl, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; wherein each R 20 and R 21 is selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; alternatively two R 10 and R 11 together with the
  • the invention relates to a prodrug of a secondary amine containing parent drug having the formula:
  • n is an integer between about 1 and about 50; each R 10 and R 11 is independently selected from absent, hydrogen, halogen, —OR 20 , —SR 20 , —NR 20 R 21 , —C(O)R 20 , —C(O)OR 20 , —C(O)NR 20 R 21 , —N(R 20 )C(O)R 21 , —CF 3 , —CN, —NO 2 , —N 3 , acyl, optionally substituted alkoxy, optionally substituted alkylamino, optionally substituted dialkylamino, optionally substituted alkylthio, optionally substituted alkylsulfonyl, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; wherein each R 20 and R 21 is selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; alternatively two R 10 and R 11 together with the
  • n is an integer between about 4 and about 26.
  • the invention relates to a prodrug conjugate with three drug moieties attached to a carrier group.
  • three parent drug moieties can be attached to an aconitic acid based carrier:
  • tricarboxylic acid compounds such as citric acid, isocitric acid, and trimesic acid can be used as carriers.
  • the invention relates to prodrugs having the formula:
  • API-1 and API-2 are as defined above, and API-3 is a biologically active moiety and is the same or different from API-1, and API-2.
  • the compounds of the invention are derivatives of lactam-, imide-, carbamate-, and cyclic urea-, -containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • the invention relates to a prodrug conjugate having the formula:
  • h is 3 or 4;
  • each R 100 , R 101 , R 102 , and R 103 is independently selected from absent, hydrogen, halogen, —OR 10 , —SR 10 , —NR 10 R 11 —, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; alternatively, two R 100 , and R 101 together form an optionally substituted carbocyclic or heterocyclyl ring; C1 is as previously defined; and,
  • X 100 is —CH— or —N—.
  • the invention relates to a prodrug conjugates having the formula:
  • D together with oxygen to which it is attached forms a biologically active moiety; and, D 2 together with oxygen to which it is attached forms a biologically active moiety; and C1 is as previously defined.
  • the invention relates to a prodrug conjugate having the formula:
  • n is selected from 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30.
  • the parent drug moieties are selected from Table 1.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-1.
  • both API-1 and API-2 represent the same parent drug.
  • the parent drug moieties are selected from Table 2.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-2.
  • both API-1 and API-2 represent the same parent drug.
  • the parent drug moieties are selected from Table 3.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table 3.
  • both API-1 and API-2 represent the same parent drug.
  • the compounds suitable for use in the methods of the invention are derivatives of acylaniline-, -containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • compounds of the present invention are represented by Formula III below, or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof:
  • each R 50 , R 51 , R 52 , R 53 , R 54 and R 55 is independently selected from hydrogen, halogen, —OR 10 , —SR 10 , —NR 10 R 11 —, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; alternatively, two or more R 50 , R 51 , R 52 , R 53 , R 54 and R 55 together form an optionally substituted ring.
  • the parent drug moieties are selected from Table 4.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are independently selected from Table-4. In one embodiment both API-1 and API-2 represent the same parent drug.
  • the compounds suitable for use in the methods of the invention are derivatives of thioazolidine-, -containing parent drugs that are substituted at an amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • compounds of the present invention are represented by Formula IV below, or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof:
  • Cy 2 is an optionally substituted heterocyclic ring; and X 5 is selected from absent, —S—, —O—, —S(O)—, —S(O) 2 —, —N(R 10 )—, —C(O)—, —C(OR 10 )(R 11 )—, —[C(R 10 )(R 11 )] v —, —O[C(R 10 )(R 11 )] v —, —O[C(R 10 )(R 11 )] v O—, —S[C(R 10 )(R 11 )] v O—, —NR 12 [C(R 10 )(R 11 )] v O—, —NR 12 [C(R 10 )(R 11 )] v S—, —S[C(R 10 )(R 11 )] v —, —C(O)[C(R 10 )(R 11 )] v S
  • the parent drug moieties are independently selected from Table 5.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-5. In one embodiment both API-1 and API-2 represent the same parent drug.
  • the compounds suitable for use in the methods of the invention are derivatives of barbiturates that are substituted at an amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • the parent drug moieties are selected from Table 6.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-6.
  • both API-1 and API-2 represent the same parent drug.
  • the compounds suitable for use in the methods of the invention are derivatives of pyridine and pyrimidine containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • the parent drug moieties are selected from Table 7.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-7.
  • both API-1 and API-2 represent the same parent drug.
  • the compounds suitable for use in the methods of the invention are derivatives of benzamide containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • the parent drug moieties are independently selected from Table 8.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-8.
  • both API-1 and API-2 represent the same parent drug.
  • the compounds suitable for use in the methods of the invention are derivatives of imide containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • the parent drug moieties are independently selected from Table 9.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-9.
  • both API-1 and API-2 represent the same parent drug.
  • the compounds suitable for use in the methods of the invention are derivatives of cyclic urea-containing parent drugs that are substituted at either of the urea nitrogens or oxygen with labile aldehyde-linked prodrug moieties.
  • the parent drug moieties are independently selected from Table 10.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-10.
  • both API-1 and API-2 represent the same parent drug.
  • the compounds suitable for use in the methods of the invention are derivatives of sulfonamide parent drugs that are substituted at the sulfonamide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • a and B together with the sulfonamide group forms the parent drug; and, A2 and B2 together with the sulfonamide group form the parent drug.
  • the parent drug moieties are selected from Table 11.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are independently selected from Table-11.
  • both API-1 and API-2 represent the same parent drug.
  • the invention relates to a prodrug conjugates having the Formula V:
  • X 1 is selected from O or S;
  • X 2 is selected from direct bond, O, S or NR 20 wherein R 20 is selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl;
  • X— is a pharmaceutically acceptable counterion; and, C1 represents a carrier moiety.
  • the invention relates to a prodrug conjugates having the Formula VI:
  • n is an integer between 1 and 50; n, A 1 , E 1 , B 1 , A 2 , E 2 , B 2 , X 1 , X 2 , R 10 , R 11 and X— are as defined above.
  • n is selected from 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30.
  • the invention relates to a prodrug conjugates having the Formula VII:
  • a 1 , B 1 , A 2 , E 2 , B 2 , X 1 , X 2 , and X— are as defined above.
  • the tertiary amine-containing parent drug may be any tertiary amine-containing drug that induces a desired local or systemic effect.
  • drugs include broad classes of compounds. In general, this includes: analgesic agents; anesthetic agents; antiarthritic agents; respiratory drugs, including antiasthmatic agents; anticancer agents, including antineoplastic agents; anticholinergics; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihelminthics; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents such as antibiotics and antiviral agents; antiinflammatory agents; antimigraine preparations; antinauseants; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antitubercular agents; antiulcer agents; antiviral agents; anxiolytics; appetite suppressants; attention deficit disorder (ADD) and attention deficit hyper
  • tertiary amine-containing antibiotic parent drugs from which the prodrugs of the invention may be derived include: clindamycin, ofloxacin/levofloxacin, pefloxacin, quinupristine, rolitetracycline, and cefotiam.
  • tertiary amine-containing antifungal parent drugs from which the prodrugs of the invention may be derived include: butenafine, naftifine, and terbinafine.
  • tertiary amine-containing antimalarials and antiprotozoals parent drugs from which the prodrugs of the invention may be derived include: amodiaquine, quinacrine, sitamaquine, quinine.
  • tertiary amine-containing HIV protease inhibitor parent drugs from which the prodrugs of the invention may be derived include: saquinavir, indinavir, atazanavir and nelfinavir.
  • Anti-HIV drugs also include maraviroc and aplaviroc for inhibition of HIV entry.
  • tertiary amine-containing anticonvulsants/antispasmodics parent drugs from which the prodrugs of the invention may be derived include: atropine, darifenancin; dicyclomine; hyoscayamine, tiagabine, flavoxate; and alverine.
  • tertiary-amine containing antidepressant parent drugs from which the prodrugs of the invention are derived include: amitriptyline, adinazolam, citalopram, cotinine, clomipramine, doxepin, escitalopram, femoxetine, imipramine, minaprine, moclobemide, mianserin, mirtazapine, nefazodone, nefopam, pipofenazine, promazine, ritanserin, trazodone, trimipramine and venlafaxine.
  • tertiary amine-containing antiemetic parent drugs from which the prodrugs of the invention are derived include: aprepitant, buclizine, cilansetron, cyclizine, dolasetron, granisetron, meclizine, ondansetron, palonosetron, ramosetron, thiethylperazine, trimethobenzamide, scopolamine, and prochlorperazine.
  • tertiary amine-containing antihistamine parent drugs from which the prodrugs of the invention are derived include: acetprometazine, azatadine, azelastine, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, dexobrompheniramine, diphenhydramine, diphenylpyraline, doxepin, emadastine, loratadine, mequitazine, olopatadine, phenindamine, pheniramine, promethazine, tripelennamine, triprolidine, astemizole, cetirizine, fexofenadine, terfenadine, latrepirdine, ketotifen, cyproheptadine, hydroxyzine, clobenzepam doxylamine, cinnarizine, orphenadrine.
  • tertiary amine-containing antiparkinsonian parent drugs from which prodrugs of the invention are derived include: cabergoline, ethopropazine, pergolide, selegiline, metixene, biperiden, cycrimine, procycladine and apomorphine.
  • tertiary amine-containing antipsychotic parent drugs from which prodrugs of the invention are derived include: acetophenazine, amisulpride, aripiprazole, bifeprunox, blonanserin, cariprazine, carphenazine, clopenthixol, clozapine, dehydro aripiprazole, someperidone, droperidol, flupenthixol, fluphenazine, fluspirilene, haloperidol, iloperidone, lurasidone, mesoridazine, molindole, nemanopride, olanzapine, perospirone, perphenazine, PF-00217830 (Pfizer), pipotiazine, propericiazine, quetiapine, remoxipride, risperidone, sertindole, SLV-313 (Solvay/Wyeth),
  • tertiary amine-containing anxiolytic parent drugs from which prodrugs of the invention are derived include: buspirone, and loxapine.
  • tertiary amine-containing nootroopic (memory and cognitive enhancers) parent drugs from which prodrugs of the invention are derived include: donepezil, galantamine, latrepirdine, nicotine, TC-5616 (Targacept, Inc.) having the IUPAC name: N-[(2S,3S)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide.
  • tertiary amine-containing parent drugs for erectile dysfunction from which prodrugs of the invention are derived include: apomorphine and sildenafil.
  • tertiary amine-containing parent drugs for migraine headache from which prodrugs of the invention are derived include: almotriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergotamine, ergotamine, eletripan and lisuride.
  • tertiary amine-containing parent drugs for the treatment of alcoholism from which prodrugs of the invention are derived include: naloxone and naltrexone.
  • Other narcotic antagonist amine containing parent drugs for treatment of substance abuse from which prodrugs of the invention are derived include: levallorphan, nalbuphine, nalorphine and nalmefene.
  • Examples of a tertiary amine-containing parent drug for the treatment of addiction from which a prodrug of the invention is derived include: buprenorphine, isomethadone, levomethadyl acetate, methadyl acetate, nor-acetyl levomethadol, and normethadone.
  • tertiary amine-containing muscle relaxant parent drugs from which prodrugs are derived include: cyclobenzaprine, nefopam, tolperisone, orphenadrine, and quinine.
  • tertiary amine-containing nonsteroidal anti-inflammatory parent drugs from which prodrugs of the invention are derived include: etodolac, meloxicam, ketorolac, lornoxicam and tenoxicam.
  • tertiary amine-containing opioid parent drugs from which prodrugs of the invention are derived include alfentanil, anileridine, buprenorphine, butorphanol, clonitazene, codeine, dihydrocodeine, dihydromorphin, fentanyl, hydromorphone, meperidine, metazocine, methadone, morphine, oxycodone, hyrdocodone, oxymorphone, pentazocine, remifentanil, and sufentanil.
  • Examples of other tertiary amine-containing analgesic parent drugs from which prodrugs of the invention are derived include: methotrimeprazine, tramadol, nefopam, phenazocine, propiram, quinupramine, thebaine and propoxyphene.
  • tertiary amine-containing sedatives/hypnotics from which the prodrugs of the invention may be derived include: eszopiclone, flurazepam, propiomazine, and zopiclone.
  • tertiary amine-containing local analgesic parent drugs from which prodrugs of the invention are derived include: bupivacaine, dexmedetomidine, dibucaine, dyclonine, lodicaine, mepivacaine, procaine, and tapentadol and ropivacaine.
  • tertiary amine-containing antianginals from which the prodrugs of the invention may be derived include: ranozaline, bepridil.
  • tertiary amine-containing antiarrhythmics from which the prodrugs of the invention may be derived include: amiodarone, aprindine, encainide, moricizine, procainamide, diltiazem, verapamil, bepridil.
  • tertiary amine-containing antihypertensives from which the prodrugs of the invention may be derived include: azelnidipine, deserpidine, ketanserin, reserpine, and sildenafil.
  • tertiary amine-containing antithrombotics examples include: clopidogrel and ticlopidine.
  • tertiary amine-containing antineoplastic parent drugs from which prodrugs of the invention are derived include: dasatinib, flavopiridol, gefitinib, imatinib, sunitinib, topotecan, vinblastine, vincristine, fincesine, vinorelbine, vinorelbine, tamoxifen, tremifene, and tesmilifene.
  • tertiary amine-containing drugs parent drugs for use in treating irritable bowel syndrome (IBS) from which the prodrugs of the invention are derived include asimadoline.
  • Examples of other tertiary amine-containing parent drugs from which the prodrugs of the invention are derived include: antimuscarinics and anticholinergics such as benzotropine, procyclidine and trihexylphanidyl; alpha andrenergic blockers such as dapiprazole, dexmedetomidine and nicergoline; anorexics such as diethylpropian, benzapehtamine, phendimetrazine, and sibutramine; antidiarrhels such as diphenoxylate and loperamide, antikinetic and antihypertensives such as clonidine; antiosteoporotics such as raloxifene; antipruritics such as methyldilazine; antitussives such as dextromethorphan; antiulceratives such as pirenzepine; cholinesterase inhibitors such as galantamine; gastroprokinetics such as alvimopan, cisa
  • Preferred tertiary amine-containing parent drugs from which prodrugs of the invention are derived include: amisulpride, aripiprazole, asenapine, cariprazine, citalopram, dehydroaripiprazole, escitalopram, galantamine, iloperidone, latrepirdine, olanzapine, paliperidone, perospirone, risperidone, and ziprasidone.
  • the present invention is intended to encompass any parent drug compound or any substituted parent drug compound which contains a tertiary amine group and which is biologically active and can be derivatized according to the present invention to afford the corresponding prodrugs.
  • the tertiary amine-containing parent drugs from which the prodrugs of the invention may be derived are numerous, many of the chemical structures of the prodrugs of the invention can be characterized by certain general structure types.
  • One type includes those wherein the tertiary amine nitrogen is part of a cyclic (including bicyclic or tricyclic) aliphatic group such as piperidine, piperazine, morpholine, pyrrolidine, azapine, and diazapine.
  • Another type includes those wherein the tertiary amine nitrogen is part of an alkyl amine group such as a diethyl and/or dimethyl amine.
  • the invention relates to a prodrug conjugates having the Formula VIII:
  • A— is a pharmaceutically acceptable counterion
  • X 1 , and X 2 are as defined above.
  • the parent drug moieties are independently selected from Table 12.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-12.
  • both API-1 and API-2 represent the same parent drug.
  • the compounds suitable for use in the methods of the invention are derivatives of heteroaryl NH-containing parent drugs that are substituted at the NH nitrogen atom with labile prodrug moieties.
  • the prodrug moieties are hydrophobic and reduce the solubility at physiological pH (pH 7.0), as well as modulate polarity and lipophilicity parameters of the prodrug as compared to the parent drug.
  • the invention provides a prodrug compound of Formula IX:
  • each of X 10 to X 17 is independently N or CR, provided that at least one of X 10 -X 17 is CR.
  • the R groups combine to form the portion of the prodrug compound in addition to the five-membered heteroaromatic ring.
  • the R groups can be independently hydrogen, optionally substituted aliphatic, aromatic, heteroaromatic or a combination thereof.
  • the R groups can also be taken together with the carbon atoms to which they are attached to form one or more optionally substituted fused ring systems.
  • the invention relates to a prodrug conjugate of Formula X:
  • n, X 10 -X 17 , X 1 , X 2 , R 10 , and R 11 are as defined above.
  • Heteroaromatic NH-containing parent drugs include broad classes of compounds. In general, this includes: analgesic agents; anesthetic agents; antiarthritic agents; respiratory drugs, including antiasthmatic agents; anticancer agents, including antineoplastic agents; anticholinergics; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihelminthics; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents such as antibiotics and antiviral agents; antiinflammatory agents; antimigraine preparations; antinauseants; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antitubercular agents; antiulcer agents; antiviral agents; anxiolytics; appetite suppressants; attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) drugs; cardiovascular preparations including calcium channel blockers, CNS agents; beta-blockers and antiar
  • Specific heteroaromatic NH-containing parent drugs represent a variety of drug classes.
  • Such drugs include tranquilizers and sedatives, such as mepiprazole and dexmedetomidine; anthelmintic agents, such as albendazole, carbendazole, cyclobendazole, mebendazole and thiabendazole; antimigraine agents, such as almotriptan, dolasetron, eletriptan, lisuride, naratriptan, rizatriptan, sumatriptan, frovatriptan, zolmitriptan and ergotamine; treatments for irritable bowel syndrome, such as alosetron; antiviral agents, such as delavirdine and atevirdine; antihypertensive agents, such as bopindolol, bucindolol, candesartan, deserpidine, mibefradil, ergoloid mesylate, indoramin, irbes
  • the parent drug is a peptide comprising at least one heteroaromatic NH group.
  • Such peptides include peptides comprising from 2 to about 50, from 2 to about 40, from 2 to about 20 or from 2 to about 12 amino acid residues, including at least one residue selected from tryptophan and histidine.
  • Suitable peptides include, but are not limited to, thyrotropin releasing hormone (TRH), exenatide, daptomycin, octreotide, somatostatin, teriparatide, leuprorelin and goserelin.
  • TRH thyrotropin releasing hormone
  • heteroaromatic NH-containing parent drugs from which the prodrugs of the invention may be derived are numerous, many of the chemical structures of the prodrugs of the invention can be characterized by certain general structure types.
  • One type includes compounds wherein the heteroaromatic group is a pyrrole group.
  • Another type includes compounds wherein the heteroaromatic group is an imidazole group.
  • Another type includes compounds wherein the heteroaromatic group is a 1,2,3- or 1,2,4-triazole group.
  • Another type includes compounds wherein the heteroaromatic group is a tetrazole group.
  • Another type includes compounds wherein the heteroaromatic group is a benzimidazole group.
  • Another type includes compounds wherein the heteroaromatic group is an indole group.
  • Another type includes compounds wherein the heteroaromatic group is a pyrazole group.
  • Benzimidazole-containing parent drugs which can be modified to produce prodrugs of the invention include albenazole, carbendazole, cyclobendazole, lansoprazole, liarozole, mebendazole, mizolastine, omeprazole, pantaprazole, pimobendan, rabeprazole, thiabendazole, bendazol and mibepradil.
  • Preferred benzimidazole-containing drugs include lansoprazole, mibefradil and pimobendan.
  • Imidazole-containing parent drugs which can be modified to produce prodrugs of the invention include alosetron, ambuphylline, cimetidine, conivaptan, dexmedetomidine, ramosetron, thiamiprine, sulmazole, azathioprine, exenatide, teriparatide, thyrotropin releasing hormone (TRH), goserelin and leuprorelin.
  • Preferred imidazole-containing drugs include conivaptan, sulmazole and azathioprine.
  • Indole-containing parent drugs which can be modified to produce prodrugs of the invention include almotriptan, atevirdine, bopindolol, bromocriptine, bucindolol, cabergoline, delavirdine, deserpidine, dolasetron, eletriptan, ergoloid mesylate, ergonovine, etodolac, frovatriptan, indoramin, lisuride, mepidolol, methylergonovine, naratriptan, oxypertine, pemetrexed, pergolide, rescinnamine, reserpine, rizatriptan, sumatriptan, tadalafil, tropisetron, adrenoglomerulotriptan, bromocriptine, ergotamine, indalpine, raubasine, reserpiline, roxindole, syrosingopine,
  • Preferred indole-containing drugs include bopindolol, bucindolol, cabergoline, dolasetron, indoramin, oxypertine, pergolide, rescinnamine, reserpine, atevirdine, carmoxirole and rescimetol.
  • Pyrazole-containing parent drugs which can be modified to produce prodrugs of the invention include mepiprazole and allopurinlol.
  • Tetrazole-containing parent drugs which can be modified to produce prodrugs of the invention include candesartan, irbesartan, losartan, olmesartan, pemirolast, pranlukast, tasosartan, traxanox and valsartan.
  • Triazole-containing parent drugs which can be modified to produce prodrugs of the invention include cefatrizine and alizapride.
  • Particularly preferred parent drugs which can be modified according to the invention include bopindolol, bucindolol, cabergoline, candesartan, cefatrizine, conivaptan, indoramin, irbesartan, lansoprazole, mibefradil, olmesartan, oxypertine, pemirolast, pergolide, pimobendan, rescinnamine, reserpine, valsartan, sulmazole, azathioprine, atevirdine, carmoxirole and rescimetol.
  • the parent drug moieties are selected from Table 13.
  • the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table 13.
  • both API-1 and API-2 represent the same parent drug.
  • each LG-1 and LG-2 is independently a leaving group, preferably a chloride, bromide or iodide.
  • Scheme 2 a general method to synthesize prodrugs that can be linked to two parent drug molecules through alkyl group is provided (Scheme 2).
  • Scheme 2 a general method to synthesize prodrugs that can be linked to two parent drug molecules through alkyl group is provided (Scheme 2).
  • the same methodology can be used to synthesize prodrugs with branched and substituted alkyl groups.
  • n is an integer between about 1 and about 50, preferably between about 4 and about 26.
  • the dicarboxylic acid from Scheme 2 is selected from oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, undecanedioic acid, dodecanedioic acid, ortho-, para- or meta-phthalic acid, maleic acid, fumaric acid, glutaconic acid, traumatic acid or muconic acid.
  • the dicarboxylic acid is reacted with one mole equivalent or less of thionyl chloride to give a mixture of mono and disubstituted acid chloride.
  • the dicarobxylic acid is reacted with two or more mole equivalents of thionyl chloride.
  • the acid chlorides can be converted to chloromethyl esters by reacting with trioxane or paraformaldehyde using zirconium tetrachloride as the Lewis acid. (Mudryk, B. et. al., Tetrahedron Letters 43(36), 2002, 6317-6318).
  • the chloromethyl esters can be reacted with reactive APIs, such as amine containing pharmacophores to give the final conjugates.
  • reactive APIs such as amine containing pharmacophores
  • a general method to synthesize prodrugs of aripiprazole that can be linked to two aripiprazole molecules through alkyl group is provided (Scheme 3).
  • the invention further provides a prodrug of aripiprazole selected from Table 14.
  • the compounds of Formula I, IA or IB are less soluble, and are preferably at least an order of magnitude less soluble, as compared to the parent drug from which they were derived.
  • the prodrugs of Formula I, IA or IB have an aqueous solubility of less than about 0.5 mg/ml, preferably less than about 0.1 mg/mL, preferably less than about 0.01 mg/mL, preferably less than about 0.001 mg/mL, preferably less than about 0.0001 mg/mL and even more preferably less than about 0.00001 mg/ml when solubility is measured in a phosphate buffer (pH 7.4) at room temperature.
  • a compound of the invention provides sustained delivery of the parent drug over hours, days, weeks or months when administered, for example, orally or parenterally, to a subject.
  • the compounds can provide sustained delivery of the parent drug for at least 8, 12, 24, 36 or 48 hours or at least 4, 7, 15, 30, 60, 75 or 90 days or longer.
  • a prodrug of the invention may further comprise a sustained release delivery system for providing additional protection of the prodrug from enzymatic or chemical degradation.
  • the invention provides a method for sustained delivery of a parent lactam, amide, imide, sulfonamide, carbamate, urea, benzamide, or acylaniline containing drug to a subject in need thereof.
  • Each of these groups comprises an amidic N—H group.
  • the method comprises administering to the subject an effective amount of a prodrug formed by substituting on the NH group a labile, hydrophobic aldehyde-linked prodrug moiety wherein the prodrug has reduced solubility under physiological conditions compared to the parent drug and provides for longer sustained therapeutic levels of the parent drug following administration than observed levels following administration of the parent drug.
  • the amidic N—H group has a pKa of about 5 to about 22, preferably about 5 to about 21, and preferably about 5 to about 20.
  • the invention further relates to prodrugs of secondary amine containing drugs of Formula LI:
  • the invention relates to a prodrug conjugate having the formula:
  • the invention relates to a prodrug of a secondary amine containing parent drug having the Formula LI-A:
  • n is an integer between about 1 and about 50;
  • X 1 is S or O
  • X 2 is selected from direct bond, O, S or NR 20 ; each R 10 and R 11 is independently selected from absent, hydrogen, halogen, —OR 20 , —SR 20 , —NR 20 R 21 , —C(O)R 20 , —C(O)OR 20 , —C(O)NR 20 R 21 , —N(R 20 )C(O)R 21 , —CF 3 , —CN, —NO 2 , —N 3 , acyl, optionally substituted alkoxy, optionally substituted alkylamino, optionally substituted dialkylamino, optionally substituted alkylthio, optionally substituted alkylsulfonyl, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; wherein each R 20 and R 21 is selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; alternatively two R 10 and R
  • n is selected from 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30.
  • the secondary amine-containing parent drugs can be any secondary amine-containing parent drug that induces a desired local or systemic effect.
  • Such parent drugs include broad classes of compounds.
  • respiratory drugs including antiasthmatic agents; analgesic agents; antidepressants; antianginal agents; antiarrhythmic agents; antihypertensive agents; antidiabetic agents; antihistamines; anti-infective agents such as antibiotics; antiinflammatory agents; antiparkinsonism drugs; antipsychotics; antipyretic agents; antiulcer agents; attention deficit hyperactivity disorder (ADHD) drugs; central nervous system stimulants; cough and cold preparations, including decongestants; and psychostimulants.
  • respiratory drugs including antiasthmatic agents; analgesic agents; antidepressants; antianginal agents; antiarrhythmic agents; antihypertensive agents; antidiabetic agents; antihistamines; anti-infective agents such as antibiotics; antiinflammatory agents; antiparkinsonism drugs; antipsychotics; antipyretic
  • secondary-amine containing parent drugs from which prodrugs of the invention may be derived include: alprenolol, acebutolol, amidephrine, amineptine, amosulalol, amoxapine, amphetaminil, atenolol, atomoxetine, balofloxacin, bamethan, befunolol, benazepril, benfluorex, benzoctamine, betahistine, betaxolol, bevantolol, bifemelane, bisoprolol, brinzolamide, bufeniode, butethamine, camylofine, carazolol, carticaine, carvedilol, cephaeline, ciprofloxacin, clozapine, clobenzorex, clorprenaline, cyclopentamine, delapril, demexiptiline, denopamine, desipramine,
  • Preferred secondary amine-containing parent drugs from which prodrugs of the invention are derived include atenolol, atomoxetine, clozapine, desipramine, desloratadine (clarinex), diclofenac, doripenem, duloxetine, enalapril, ertapenem, fluoxetine, metoprolol, mecamylamine, meropenem, methylphenidate, dtmp (dextrorotary methylphenidate), olanzapine, paroxetine, pramipexole, rasagiline, ®-RASAGILINE, salbutamol/albuterol, tamsulosin, varenicline (hantix), and vildagliptin.
  • the secondary amine-containing parent drug is selected from clozapine, duloxetine, mecamylamine, pramipexole, rasagiline, ®-RASAGILINE, and
  • the parent drug moieties are selected from Table 14.
  • the prodrug is a compound of Formula LI or LI-A wherein API-1 and API-2 are selected from Table 14. In one embodiment both API-1 and API-2 represent the same parent drug.
  • the invention relates to a prodrug of olanzapine represented by formula:
  • the invention relates to a prodrug of olanzapine represented by formula:
  • the invention relates to a prodrug of olanzapine represented by formula:
  • the invention relates to a prodrug of olanzapine represented by formula:
  • the invention relates to a prodrug of olanzapine represented by formula:
  • the invention relates to a prodrug of olanzapine represented by formula:
  • the invention relates to a prodrug of olanzapine represented by formula:
  • the invention relates to a prodrug of olanzapine represented by formula:
  • the invention relates to a prodrug of olanzapine represented by formula:
  • the invention relates to a prodrug of olanzapine represented by formula:
  • the compounds of the invention can be synthesized by the method set forth in Schemes 3A and 3B where derivatization of olanzapine is illustrated.
  • Schemes 3A and 3B illustrate the synthesis of a compound of Formula LI by condensation of the parent drug, olanzapine, with chloromethyl chloroformate, followed by condensation with a carboxylic acid.
  • linking the drug molecule to a carrier moiety proceeds via substitution at an oxygen or nitrogen atom of the parent drug molecule with loss of a hydrogen atom.
  • the parent drug moiety is the radical resulting from removal of the O—H or N—H hydrogen atom from the parent drug molecule.
  • the carrier moiety is linked to the parent drug molecule without any loss of atoms from the parent drug molecule.
  • the parent drug moiety includes the entire structure of the parent drug compound.
  • a loss of hydrogen from the parent drug doesn't occur.
  • aliphatic group refers to a non-aromatic moiety that may be saturated (e.g., single bond) or contain one or more units of unsaturation, e.g., double and/or triple bonds.
  • An aliphatic group may be straight chained, branched or cyclic, contain carbon, hydrogen or, optionally, one or more heteroatoms and may be substituted or unsubstituted.
  • aliphatic groups include, for example, polyalkoxyalkyls, such as polyalkylene glycols, polyamines, and polyimines, for example. Such aliphatic groups may be further substituted.
  • aliphatic groups may include alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, and substituted or unsubstituted cycloalkyl groups as described herein.
  • acyl refers to a carbonyl substituted with hydrogen, alkyl, partially saturated or fully saturated cycloalkyl, partially saturated or fully saturated heterocycle, aryl, or heteroaryl.
  • acyl includes groups such as (C 1 -C 6 ) alkanoyl (e.g., formyl, acetyl, propionyl, butyryl, valeryl, caproyl, t-butylacetyl, etc.), (C 3 -C 6 )cycloalkylcarbonyl (e.g., cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, etc.), heterocyclic carbonyl (e.g., pyrrolidinylcarbonyl, pyrrolid-2-one-5-carbonyl, piperidinylcarbonyl, piperazinylcarbonyl, tetrahydrofuranylcarbony
  • alkyl, cycloalkyl, heterocycle, aryl and heteroaryl portion of the acyl group may be any one of the groups described in the respective definitions.
  • the acyl group may be unsubstituted or optionally substituted with one or more substituents (typically, one to three substituents) independently selected from the group of substituents listed below in the definition for “substituted” or the alkyl, cycloalkyl, heterocycle, aryl and heteroaryl portion of the acyl group may be substituted as described above in the preferred and more preferred list of substituents, respectively.
  • alkyl is intended to include both branched and straight chain, substituted or unsubstituted saturated aliphatic hydrocarbon radicals/groups having the specified number of carbons.
  • Preferred alkyl groups comprise about 1 to about 24 carbon atoms (“C 1 -C 24 ”) preferably about 7 to about 24 carbon atoms (“C 7 -C 24 ”), preferably about 8 to about 24 carbon atoms (“C 8 -C 24 ”), preferably about 9 to about 24 carbon atoms (“C 9 -C 24 ”).
  • C 1 -C 8 carbon atoms
  • C 1 -C 6 carbon atoms
  • C 1 -C 3 carbon atoms
  • Examples of C 1 -C 6 alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, neopentyl and n-hexyl radicals.
  • alkenyl refers to linear or branched radicals having at least one carbon-carbon double bond. Such radicals preferably contain from about two to about twenty-four carbon atoms (“C 2 -C 24 ”) preferably about 7 to about 24 carbon atoms (“C 7 -C 24 ”), preferably about 8 to about 24 carbon atoms (“C 8 -C 24 ”), and preferably about 9 to about 24 carbon atoms (“C 9 -C 24 ”).
  • Other preferred alkenyl radicals are “lower alkenyl” radicals having two to about ten carbon atoms (“C 2 -C 10 ”) such as ethenyl, allyl, propenyl, butenyl and 4-methylbutenyl.
  • Preferred lower alkenyl radicals include 2 to about 6 carbon atoms (“C 2 -C 6 ”).
  • alkenyl and “lower alkenyl”, embrace radicals having “cis” and “trans” orientations, or alternatively, “E” and “Z” orientations.
  • alkynyl refers to linear or branched radicals having at least one carbon-carbon triple bond. Such radicals preferably contain from about two to about twenty-four carbon atoms (“C 2 -C 24 ”) preferably about 7 to about 24 carbon atoms (“C 7 -C 24 ”), preferably about 8 to about 24 carbon atoms (“C 8 -C 24 ”), and preferably about 9 to about 24 carbon atoms (“C 9 -C 24 ”).
  • Other preferred alkynyl radicals are “lower alkynyl” radicals having two to about ten carbon atoms such as propargyl, 1-propynyl, 2-propynyl, 1-butyne, 2-butynyl and 1-pentynyl.
  • Preferred lower alkynyl radicals include 2 to about 6 carbon atoms (“C 2 -C 6 ”).
  • cycloalkyl refers to saturated carbocyclic radicals having three to about twelve carbon atoms (“C 3 -C 12 ”).
  • cycloalkyl embraces saturated carbocyclic radicals having three to about twelve carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • cycloalkenyl refers to partially unsaturated carbocyclic radicals having three to twelve carbon atoms. Cycloalkenyl radicals that are partially unsaturated carbocyclic radicals that contain two double bonds (that may or may not be conjugated) can be called “cycloalkyldienyl”. More preferred cycloalkenyl radicals are “lower cycloalkenyl” radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl and cyclohexenyl.
  • alkylene refers to a divalent group derived from a straight chain or branched saturated hydrocarbon chain having the specified number of carbons atoms.
  • alkylene groups include, but are not limited to, ethylene, propylene, butylene, 3-methyl-pentylene, and 5-ethyl-hexylene.
  • alkenylene denotes a divalent group derived from a straight chain or branched hydrocarbon moiety containing the specified number of carbon atoms having at least one carbon-carbon double bond.
  • Alkenylene groups include, but are not limited to, for example, ethenylene, 2-propenylene, 2-butenylene, 1-methyl-2-buten-1-ylene, and the like.
  • alkynylene denotes a divalent group derived from a straight chain or branched hydrocarbon moiety containing the specified number of carbon atoms having at least one carbon-carbon triple bond.
  • Representative alkynylene groups include, but are not limited to, for example, propynylene, 1-butynylene, 2-methyl-3-hexynylene, and the like.
  • alkoxy refers to linear or branched oxy-containing radicals each having alkyl portions of one to about twenty-four carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkoxy radicals are “lower alkoxy” radicals having one to about ten carbon atoms and more preferably having one to about eight carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy.
  • alkoxyalkyl refers to alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals.
  • aryl alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused.
  • aryl embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl.
  • heterocyclyl refers to saturated, partially unsaturated and unsaturated heteroatom-containing ring-shaped radicals, which can also be called “heterocyclyl”, “heterocycloalkenyl” and “heteroaryl” correspondingly, where the heteroatoms may be selected from nitrogen, sulfur and oxygen.
  • saturated heterocyclyl radicals include saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms (e.g., pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g., morpholinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., thiazolidinyl, etc.).
  • heterocyclyl radicals examples include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole.
  • Heterocyclyl radicals may include a pentavalent nitrogen, such as in tetrazolium and pyridinium radicals.
  • the term “heterocycle” also embraces radicals where heterocyclyl radicals are fused with aryl or cycloalkyl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like.
  • heteroaryl refers to unsaturated aromatic heterocyclyl radicals.
  • heteroaryl radicals include unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.; unsaturated condensed heterocyclyl group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl,
  • heterocycloalkyl refers to heterocyclo-substituted alkyl radicals. More preferred heterocycloalkyl radicals are “lower heterocycloalkyl” radicals having one to six carbon atoms in the heterocyclo radical.
  • alkylthio refers to radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms attached to a divalent sulfur atom.
  • Preferred alkylthio radicals have alkyl radicals of one to about twenty-four carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkylthio radicals have alkyl radicals which are “lower alkylthio” radicals having one to about ten carbon atoms. Most preferred are alkylthio radicals having lower alkyl radicals of one to about eight carbon atoms. Examples of such lower alkylthio radicals include methylthio, ethylthio, propylthio, butylthio and hexylthio.
  • aralkyl or “arylalkyl” refer to aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl.
  • aryloxy refers to aryl radicals attached through an oxygen atom to other radicals.
  • aralkoxy or “arylalkoxy” refer to aralkyl radicals attached through an oxygen atom to other radicals.
  • aminoalkyl refers to alkyl radicals substituted with amino radicals.
  • Preferred aminoalkyl radicals have alkyl radicals having about one to about twenty-four carbon atoms or, preferably, one to about twelve carbon atoms. More preferred aminoalkyl radicals are “lower aminoalkyl” that have alkyl radicals having one to about ten carbon atoms. Most preferred are aminoalkyl radicals having lower alkyl radicals having one to eight carbon atoms. Examples of such radicals include aminomethyl, aminoethyl, and the like.
  • alkylamino denotes amino groups which are substituted with one or two alkyl radicals.
  • Preferred alkylamino radicals have alkyl radicals having about one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkylamino radicals are “lower alkylamino” that have alkyl radicals having one to about ten carbon atoms. Most preferred are alkylamino radicals having lower alkyl radicals having one to about eight carbon atoms.
  • Suitable lower alkylamino may be monosubstituted N-alkylamino or disubstituted N,N-alkylamino, such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino or the like.
  • substituted refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy
  • chemical moieties that are defined and referred to throughout can be univalent chemical moieties (e.g., alkyl, aryl, etc.) or multivalent moieties under the appropriate structural circumstances clear to those skilled in the art.
  • an “alkyl” moiety can be referred to a monovalent radical (e.g.
  • a bivalent linking moiety can be “alkyl,” in which case those skilled in the art will understand the alkyl to be a divalent radical (e.g., —CH 2 —CH 2 —), which is equivalent to the term “alkylene.”
  • divalent moieties are required and are stated as being “alkoxy”, “alkylamino”, “aryloxy”, “alkylthio”, “aryl”, “heteroaryl”, “heterocyclic”, “alkyl” “alkenyl”, “alkynyl”, “aliphatic”, or “cycloalkyl”
  • alkoxy”, “alkylamino”, “aryloxy”, “alkylthio”, “aryl”, “heteroaryl”, “heterocyclic”, “alkyl”, “alkenyl”, “alkynyl”, “aliphatic”, or “cycloalkyl” refer to the terms
  • halogen refers to an atom selected from fluorine, chlorine, bromine and iodine.
  • drug and “prodrug” as used herein all include pharmaceutically acceptable salts, co-crystals, solvates, hydrates, polymorphs, enantiomers, diastereoisomers, racemates and the like of the compounds, drugs and prodrugs having the formulas as set forth herein.
  • Substituents indicated as attached through variable points of attachments can be attached to any available position on the ring structure.
  • the term “effective amount of the subject compounds,” with respect to the subject method of treatment, refers to an amount of the subject compound which, when delivered as part of desired dose regimen, brings about management of the disease or disorder to clinically acceptable standards.
  • Treatment refers to an approach for obtaining beneficial or desired clinical results in a patient.
  • beneficial or desired clinical results include, but are not limited to, one or more of the following: alleviation of symptoms, diminishment of extent of a disease, stabilization (i.e., not worsening) of a state of disease, preventing spread (i.e., metastasis) of disease, preventing occurrence or recurrence of disease, delay or slowing of disease progression, amelioration of the disease state, and remission (whether partial or total).
  • labile refers to the capacity of the prodrug of the invention to undergo enzymatic and/or chemical cleavage in vivo thereby forming the parent drug.
  • prodrug means a compounds as disclosed herein which is a labile derivative compound of a parent drug which when administered to a patient in vivo becomes cleaved by chemical and/or enzymatic hydrolysis thereby forming the parent drug such that a sufficient amount of the compound intended to be delivered to the patient is available for its intended therapeutic use in a sustained release manner.
  • dendrimer refers to a class of highly branched, often spherical, macromolecular polymers that exhibit greater monodispersity (i.e., a smaller range of molecular weights, sizes, and shapes) than linear polymers of similar size.
  • These three-dimensional oligomeric structures are prepared by reiterative reaction sequences starting from a core molecule (such as diaminobutane or ethylenediamine) that has multiple reactive groups. When monomer units, also having multiple reactive groups, are reacted with the core, the number of reactive groups comprising the outer bounds of the dendrimer increases.
  • Successive layers of monomer molecules may be added to the surface of the dendrimer, with the number of branches and reactive groups on the surface increasing geometrically each time a layer is added.
  • the number of layers of monomer molecules in a dendrimer may be referred to as the “generation” of the dendrimer.
  • the total number of reactive functional groups on a dendrimer's outer surface ultimately depends on the number of reactive groups possessed by the core, the number of reactive groups possessed by the monomers that are used to grow the dendrimer, and the generation of the dendrimer.
  • compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers or excipients.
  • the term “pharmaceutically acceptable carrier or excipient” means a non-toxic, inert solid, semi-solid, gel or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; cyclodextrins such as alpha-( ⁇ ), beta-( ⁇ ) and gamma-( ⁇ ) cyclodextrins; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethylene glycol; est
  • compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • administration is parenteral administration by injection.
  • compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
  • pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as wetting agents, e
  • Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable suspension or emulsion, such as INTRALIPID®, LIPOSYN® or OMEGAVEN®, or solution, in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • INTRALIPID® is an intravenous fat emulsion containing 10-30% soybean oil, 1-10% egg yolk phospholipids, 1-10% glycerin and water.
  • LIPOSYN® is also an intravenous fat emulsion containing 2-15% safflower oil, 2-15% soybean oil, 0.5-5% egg phosphatides 1-10% glycerin and water.
  • OMEGAVEN® is an emulsion for infusion containing about 5-25% fish oil, 0.5-10% egg phosphatides, 1-10% glycerin and water.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, USP and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • Additional sustained release in accordance with the invention may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility.
  • the rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form.
  • delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
  • injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.
  • the formulation provides a sustained release delivery system that is capable of minimizing the exposure of the prodrug to water. This can be accomplished by formulating the prodrug with a sustained release delivery system that is a polymeric matrix capable of minimizing the diffusion of water into the matrix. Suitable polymers comprising the matrix include polylactide (PLA) polymers and the lactide/glycolide (PLGA) co-polymers.
  • PLA polylactide
  • PLGA lactide/glycolide
  • the sustained release delivery system may comprise poly-anionic molecules or resins that are suitable for injection or oral delivery.
  • Suitable polyanionic molecules include cyclodextrins and polysulfonates formulated to form a poorly soluble mass that minimizes exposure of the prodrug to water and from which the prodrug slowly leaves.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and g
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound to the body.
  • dosage forms can be made by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin.
  • the rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • a therapeutic composition of the invention is formulated and administered to the patient in solid or liquid particulate form by direct administration e.g., inhalation into the respiratory system.
  • Solid or liquid particulate forms of the active compound prepared for practicing the present invention include particles of respirable size: that is, particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and alveoli of the lungs. Delivery of aerosolized therapeutics, particularly aerosolized antibiotics, is known in the art (see, for example U.S. Pat. No. 5,767,068 to VanDevanter et al., U.S. Pat. No.
  • a “therapeutically effective amount” of a prodrug compound of the invention is meant an amount of the compound which confers a therapeutic effect on the treated subject, at a reasonable benefit/risk ratio applicable to any medical treatment.
  • the therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
  • the therapeutically effective amount of a prodrug of the invention is typically based on the target therapeutic amount of the parent drug.
  • Information regarding dosing and frequency of dosing is readily available for many parent drugs from which the prodrugs of the invention are derived and the target therapeutic amount can be calculated for each prodrug of the invention.
  • the same dose of a prodrug of the invention provides a longer duration of therapeutic effect as compared to the parent drug. Thus if a single dose of the parent drug provides 12 hours of therapeutic effectiveness, a prodrug of that same parent drug in accordance with the invention that provides therapeutic effectiveness for greater than 12 hours will be considered to achieve a “sustained release”.
  • a prodrug of the invention depends upon several factors including the nature and dose of the parent drug and the chemical characteristics of the prodrug moiety linked to the parent drug.
  • the effective dose and dose frequency of a prodrug of the invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level and dose frequency for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or contemporaneously with the specific compound employed; and like factors well known in the medical arts.
  • a mixture of Aripiprazole (5.2 g, 0.012 mol), triethylamine (0.25 mL, 0.0018 mol), 37% aqueous formaldehyde solution (18.5 mL) and dimethylformamide (50 mL) was heated at 80° C. for 48 hours. After 48 hours the reaction mixture was cooled to ambient temperature, diluted with ethyl acetate (200 mL) and washed with water (2 ⁇ 200 mL) and brine (2 ⁇ 200 mL).
  • Step-1 reaction mixture 1.0 g, 0.0021 mol
  • dichloromethane 20 mL
  • Triethylamine (1.45 mL, 0.0105 mol) was added drop wise to the above solution at 25° C. and the resulting reaction mixture was allowed to stir at the same temperature for next 10 minutes.
  • a solution of sebacoyl chloride in dichloromethane (0.223 mL, 0.00105 mol sebacoyl chloride in 2.2 mL dichloromethane) was added drop wise to the above reaction mixture at 25° C.
  • the resulting clear reaction mixture was warmed to 45° C. whereby it was allowed to stir for next 2 hours.
  • the reaction mixture was partitioned between dichloromethane (100 mL) and water (200 mL) and the aqueous layer was extracted with dichloromethane (2 ⁇ 100 mL). The combined organic fractions were washed with brine (100 mL), dried over sodium sulphate, filtered and concentrated in vacuo.
  • the product was purified by flash chromatography using dichloromethane: methanol as mobile phase and the desired product eluted at around 1.5% methanol in dichloromethane to provide Compound-6 [0.3 g, 22% yield].
  • Step-1 A solution of Step-1 (1.0 g, 0.0021 mol) in dichloromethane (20 mL) was stirred at 25° C. under nitrogen atmosphere. Triethylamine (1.45 mL, 0.0105 mol) was added drop wise to the above solution at 25° C. and the resulting reaction mixture was allowed to stir at the same temperature for next 10 minutes. After 10 minutes a solution of dodecandioyl dichloride in dichloromethane (0.280 g, 0.00105 mol dodecandioyl dichloride in 2.5 mL dichloromethane) was added drop wise to the above reaction mixture at 25° C. The resulting clear reaction mixture was warmed to 45° C. whereby it was allowed to stir for next 2 hours.
  • Oxalyl chloride (1.35 mL, 0.015 mol) was added drop wise to a solution of Tetradecandioyl dichloride (1.0 g, 0.0039 mol) in dichloromethane at 25° C. After the addition was completed, the reaction mixture was stirred at same temperature for 2 hours, the reaction mixture was partitioned between dichloromethane (100 mL) and water (200 mL), the aqueous layer was extracted with dichloromethane (2 ⁇ 100 mL).
  • Step-1 A solution of Step-1 (1.0 g, 0.0021 mol) in dichloromethane (20 mL) was stirred at 25° C. under nitrogen atmosphere. Triethylamine (1.45 mL g, 0.0105 mol) was added drop wise to the above solution at 25° C. and the resulting reaction mixture was allowed to stir at the same temperature for next 10 minutes. After 10 minutes a solution of tetradecandioyl dichloride in dichloromethane (0.308 g, 0.00105 mol tetradecandioyl dichloride in 3.0 mL dichloromethane) was added drop wise to the above reaction mixture at 25° C. The resulting clear reaction mixture was warmed to 45° C.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam-amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.

Description

    RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 13/335,405, filed Dec. 22, 2011, which claims the benefit of U.S. Provisional Application No. 61/427,026, filed on Dec. 23, 2010. The entire teachings of the above applications are incorporated herein by reference.
    • FIELD OF THE INVENTION
  • The present invention relates to prodrugs that can be linked to multiple drug molecules.
    • BACKGROUND OF THE INVENTION
  • Drug delivery systems are often critical for the safe and effective administration of a biologically active agent. Perhaps the importance of these systems is best realized when patient compliance and consistent dosing are taken under consideration. For instance, reducing the dosing requirement for a drug from four-times-a-day to a single dose per day would have significant value in terms of ensuring patient compliance and optimizing therapy. Many of the currently administered prodrugs and formulations require large amounts of drug/excipient/prodrug mixtures for administration.
  • Optimization of a drug's bioavailability has many potential benefits. For patient convenience and enhanced compliance it is generally recognized that less frequent dosing is desirable. By extending the period through which the drug is released, a longer duration of action per dose is expected. This will then lead to an overall improvement of dosing parameters such as taking a drug once a day where it has previously required four doses per day or dosing once a week or even less frequently when daily dosing was previously required. Many drugs are presently dosed once per day, but not all of these drugs have pharmacokinetic properties that are suitable for dosing intervals of exactly twenty-four hours. Extending the period through which these drugs are released would also be beneficial.
  • One of the fundamental considerations in drug therapy involves the relationship between blood levels and therapeutic activity. For most drugs, it is of primary importance that serum levels remain between a minimally effective concentration and a potentially toxic level. In pharmacokinetic terms, the peaks and troughs of a drug's blood levels ideally fit well within the therapeutic window of serum concentrations. For certain therapeutic agents, this window is so narrow that dosage formulation becomes critical.
  • In an attempt to address the need for improved bioavailability, several drug release modulation technologies have been developed. For example, poorly soluble 5,5-diphenylimidazolidine-2,4-diones have been derivatized into phosphate ester prodrugs to improve solubility (Stella et al., U.S. Pat. No. 4,260,769, 1981). Enteric coatings have been used as a protector of pharmaceuticals in the stomach and microencapsulating active agents using proteinaceous microspheres, liposomes or polysaccharides have been effective in abating enzymatic degradation of the active agent. Enzyme inhibiting adjuvants have also been used to prevent enzymatic degradation.
  • A wide range of pharmaceutical formulations provide sustained release through microencapsulation of the active agent in amides of dicarboxylic acids, modified amino acids or thermally condensed amino acids. Slow release rendering additives can also be intermixed with a large array of active agents in tablet formulations. Many of these formulations, however, deliver relatively low amounts of parent drugs in comparison with the overall weight of the formulations.
  • While microencapsulation and enteric coating technologies impart enhanced stability and time-release properties to active agent substances these technologies suffer from several shortcomings. Incorporation of the active agent is often dependent on diffusion into the microencapsulating matrix, which may not be quantitative and may complicate dosage reproducibility. In addition, encapsulated drugs rely on diffusion out of the matrix or degradation of the matrix, or both, which is highly dependent on the chemical properties and water solubility of the active agent. Conversely, water-soluble microspheres swell by an infinite degree and, unfortunately, may release the active agent in bursts with limited active agent available for sustained release. Furthermore, in some technologies, control of the degradation process required for active agent release is unreliable. For example, because an enterically coated active agent depends on pH to release the active agent and pH and residence time varies, the release rate is difficult to control.
  • Several implantable drug delivery systems have utilized polypeptide attachment to drugs. Additionally, other large polymeric carriers incorporating drugs into their matrices are used as implants for the gradual release of drugs. Yet another technology combines the advantages of covalent drug attachment with liposome formation where the active ingredient is attached to highly ordered lipid films.
  • There is a generally recognized need for sustained delivery of drugs that reduces the daily dosing requirement and allows for controlled and sustained release of the parent drug and also avoids irregularities of release and cumbersome formulations encountered with typical dissolution controlled sustained release methods. Furthermore, there is a need to accomplish the above listed goals with high relative ratios of parent drugs in relation to the dry weight of the formulation.
    • SUMMARY OF THE INVENTION
  • The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. In one embodiment, the compounds suitable for use in the methods of the invention are derivatives of heteroaryl, lactam-, amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, N-acylaniline-, and cyclic amide-, and tertiary amine containing parent drugs that are substituted at a nitrogen or oxygen atom with a labile aldehyde-linked prodrug moieties. In one embodiment, the prodrug moieties are hydrophobic and reduce the polarity and solubility of the parent drug under physiological conditions.
  • In one embodiment, the invention provides a prodrug compound of Formula I, IA or IB:
  • Figure US20160024011A1-20160128-C00001
      • wherein a is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16;
      • e is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16;
      • f is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16, wherein the sum of e and f is at least two;
      • each R1 and R2 is independently selected hydrogen, halogen, —OR20, —SR20, —NR20R21, —C(O)R20, —C(O)OR20, —C(O)NR20R21, —N(R20)C(O)R21, —CF3, —CN, —NO2, —N3, acyl, optionally substituted alkoxy, optionally substituted alkylamino, optionally substituted dialkylamino, optionally substituted alkylthio, optionally substituted alkylsulfonyl, optionally substituted aliphatic, optionally substituted aryl and optionally substituted heterocyclyl;
        • wherein each R20 and R21 is independently selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl and substituted aryl;
      • X1 is selected from O or S;
      • X2 is selected from direct bond, O, S or NR20;
      • C1 is a carrier moiety; and
      • each API is independently a biologically active moiety.
      • The invention further relates to prodrugs of secondary amine containing drugs of Formula LI:
  • Figure US20160024011A1-20160128-C00002
  • In one embodiment, each API is the same biologically active moiety. In another embodiment, the API groups represent two or more different biologically active moieties.
  • The invention further provides a method for sustained delivery of a parent drug by the administration of a conjugate of the parent drug with a labile moiety, wherein the conjugate is represented by Formula I, IA or IB.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present provides a method for attaching multiple parent drugs (biologically active moieties) to a carrier moiety resulting in a conjugate that can undergo spontaneous or enzyme assisted cleavage in physiological conditions to release the parent drug. In one embodiment, the release of the parent drug is sustained release. The sustained release is accomplished by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. In one embodiment, the prodrug moieties are hydrophobic and reduce the polarity and solubility of the parent drug under physiological conditions.
  • One of the challenges for delivering a prodrug is the high amount of prodrug needed to be dosed compared to the parent drug due to the higher molecular weight of the prodrug compared to the parent drug. Having a multivalent carrier moiety that can link two or more parent drug moieties can decrease the dose load. Also, such a multivalent carrier can link two different APIs. For example, molecules of Aripiprazole and Dehydroaripiprazole can be linked to the same carrier moiety. In another embodiment, two molecules can be linked to the same carrier so that they will be released through different mechanisms. For example, a quaternary ammonium prodrug can easily hydrolyze in physiological conditions. On the other hand, a parent drug linked through another functional group that relies on enzymatic action might release more slowly. Thus, two parent drugs can be linked to a single carrier moiety, the first via a quaternary ammonium group on one end and the second through a labile functional group. This allows one to tailor the release of the two parent drugs, with faster delivery of one parent drug compared to the other based on chemical reactivity and/or enzymatic activity.
  • In one embodiment, the invention provides a prodrug compound of Formula I, IA or IB:
  • Figure US20160024011A1-20160128-C00003
      • wherein a is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16;
      • e is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16;
      • f is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16, wherein the sum of e and f is at least two;
      • each R1 and R2 is independently selected hydrogen, halogen, —OR20, —SR20, —NR20R21, —C(O)R20, —C(O)OR20, —C(O)NR20R21, —N(R20)C(O)R21, —CF3, —CN, —NO2, —N3, acyl, optionally substituted alkoxy, optionally substituted alkylamino, optionally substituted dialkylamino, optionally substituted alkylthio, optionally substituted alkylsulfonyl, optionally substituted aliphatic, optionally substituted aryl and optionally substituted heterocyclyl;
        • wherein each R20 and R21 is independently selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl and substituted aryl;
      • X1 is selected from O or S;
      • X2 is selected from direct bond, O, S or NR20;
      • C1 is a carrier; and
      • each API is independently a biologically active moiety.
  • The invention further relates to prodrugs of secondary amine containing drugs of Formula LI:
  • Figure US20160024011A1-20160128-C00004
  • The invention further provides a method for sustained delivery of a parent drug by the administration of a multivalent conjugate of the parent drug with a labile moiety, wherein the conjugate is represented by Formula I, IA, IB or LI.
  • In some embodiments, C1 is selected from optionally substituted aliphatic, aryl or substituted aryl. In some embodiments, C1 is selected from optionally substituted C1-C30 alkyl, optionally substituted C2-C30 alkenyl, optionally substituted C1-C30 alkynyl, optionally substituted C1-C30 aryl. In some embodiments, C1 is selected from optionally substituted bicyclic heteroaryl group selected from benzofuran, benzothiophene, indole, benzimidazole, indazole, benzotriazole, pyrrolo[2,3]pyridine, imidazopyridine, pyrazolopyridine, isoindole, quinoline, isoquinoline, quinazoline, quinoxaline, phthalazine, indazole, purine, indolizine, indole, indoline, isoindoline, benzofuran and chromene. In some embodiments, C1 is a polyethyleneglycol group having a molecular weight of about 400 dalton to about 100,000 dalton.
  • In some embodiments, C1 is selected from:
  • Figure US20160024011A1-20160128-C00005
  • wherein
    c is selected from 0, 1, 2, 3 and 4;
    g is an integer from 1 to about 1,000;
    each b and d is independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13;
    s and t are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30;
    each R10, R11, R12, R13, R14, R15, and R16 is independently selected from absent, hydrogen, halogen, —OR20, —SR20, —NR20R21, —C(O)R20, —C(O)OR20, —C(O)NR20R21, —N(R20)C(O)R21, —CF3, —CN, —NO2, —N3, acyl, optionally substituted alkoxy, optionally substituted alkylamino, optionally substituted dialkylamino, optionally substituted alkylthio, optionally substituted alkylsulfonyl, optionally substituted aliphatic, optionally substituted aryl and optionally substituted heterocyclyl;
    wherein each R20 and R21 is independently selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl and substituted aryl;
    alternatively two R10, R11, R12, R13, R14, R15, and R16 together with the atoms to which they are attached may form an optionally substituted 3, 4, 5, 6 or 7 membered carbocyclic or heterocyclyl ring.
  • In some embodiments, C1 is a dendrimer.
  • In some embodiments, the invention relates to a prodrug conjugate of Formula II:
  • Figure US20160024011A1-20160128-C00006
  • wherein, each X1 is independently selected from S or O;
    each X2 is selected from absent, O, S or NR20 wherein R20 is selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl;
    API-1 is a biologically active moiety; and
    API-2 is a biologically active moiety and is the same or different from API-1.
  • In some embodiments, the invention relates to a prodrug conjugate having the formula:
  • Figure US20160024011A1-20160128-C00007
  • wherein A1 and B1 together with the nitrogen they are attached to form a first biologically active molecule; and,
    A2 and B2 together with the nitrogen they are attached to form a second biologically active molecule.
  • In some embodiments, the invention relates to a prodrug conjugate having the formula:
  • Figure US20160024011A1-20160128-C00008
  • wherein A1 and B1 together with the nitrogen they are attached to form a first biologically active molecule; and,
    A2 and B2 together with the nitrogen they are attached to form a second biologically active molecule.
  • In some embodiments, the invention relates to a prodrug conjugate having the formula:
  • Figure US20160024011A1-20160128-C00009
  • wherein n is an integer between about 1 and about 50;
    each R10 and R11 is independently selected from absent, hydrogen, halogen, —OR20, —SR20, —NR20R21, —C(O)R20, —C(O)OR20, —C(O)NR20R21, —N(R20)C(O)R21, —CF3, —CN, —NO2, —N3, acyl, optionally substituted alkoxy, optionally substituted alkylamino, optionally substituted dialkylamino, optionally substituted alkylthio, optionally substituted alkylsulfonyl, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl;
    wherein each R20 and R21 is selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl;
    alternatively two R10 and R11 together with the atoms to which they are attached may form an optionally substituted 3, 4, 5, 6 or 7 membered carbocyclic or heterocyclyl ring.
  • In some embodiments, the invention relates to a prodrug of a secondary amine containing parent drug having the formula:
  • Figure US20160024011A1-20160128-C00010
  • wherein n is an integer between about 1 and about 50;
    each R10 and R11 is independently selected from absent, hydrogen, halogen, —OR20, —SR20, —NR20R21, —C(O)R20, —C(O)OR20, —C(O)NR20R21, —N(R20)C(O)R21, —CF3, —CN, —NO2, —N3, acyl, optionally substituted alkoxy, optionally substituted alkylamino, optionally substituted dialkylamino, optionally substituted alkylthio, optionally substituted alkylsulfonyl, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl;
    wherein each R20 and R21 is selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl;
    alternatively two R10 and R11 together with the atoms to which they are attached may form an optionally substituted 3, 4, 5, 6 or 7 membered carbocyclic or heterocyclyl ring.
  • In a preferred embodiment, n is an integer between about 4 and about 26.
  • In some embodiments, the invention relates to a prodrug conjugate with three drug moieties attached to a carrier group. For example, three parent drug moieties can be attached to an aconitic acid based carrier:
  • Figure US20160024011A1-20160128-C00011
  • Other tricarboxylic acid compounds such as citric acid, isocitric acid, and trimesic acid can be used as carriers. In one embodiment, the invention relates to prodrugs having the formula:
  • Figure US20160024011A1-20160128-C00012
  • API-1 and API-2 are as defined above, and API-3 is a biologically active moiety and is the same or different from API-1, and API-2.
    • Prodrugs of Lac Tam, Cyclic Urea, Imide and Carbamate Containing Pharmacophores
  • In one embodiment, the compounds of the invention are derivatives of lactam-, imide-, carbamate-, and cyclic urea-, -containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • In some embodiments, the invention relates to a prodrug conjugate having the formula:
  • Figure US20160024011A1-20160128-C00013
  • wherein h is 3 or 4;
  • Figure US20160024011A1-20160128-C00014
    Figure US20160024011A1-20160128-C00015
  • wherein each R100, R101, R102, and R103 is independently selected from absent, hydrogen, halogen, —OR10, —SR10, —NR10R11—, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; alternatively, two R100, and R101 together form an optionally substituted carbocyclic or heterocyclyl ring;
    C1 is as previously defined; and,
    • X100 is —CH— or —N—.
  • In some embodiments, the invention relates to a prodrug conjugates having the formula:
  • Figure US20160024011A1-20160128-C00016
  • wherein D together with oxygen to which it is attached forms a biologically active moiety; and, D2 together with oxygen to which it is attached forms a biologically active moiety; and C1 is as previously defined.
  • In some embodiments, the invention relates to a prodrug conjugate having the formula:
  • Figure US20160024011A1-20160128-C00017
  • wherein n is selected from 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30.
  • In one embodiment, the parent drug moieties (APIs) are selected from Table 1. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-1. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 1
    Figure US20160024011A1-20160128-C00018
         		1
    Figure US20160024011A1-20160128-C00019
         		2
    Figure US20160024011A1-20160128-C00020
         		3
    Figure US20160024011A1-20160128-C00021
         		4
    Figure US20160024011A1-20160128-C00022
         		5
    Figure US20160024011A1-20160128-C00023
         		6
    Figure US20160024011A1-20160128-C00024
         		7
    Figure US20160024011A1-20160128-C00025
         		8
    Figure US20160024011A1-20160128-C00026
         		9
    Figure US20160024011A1-20160128-C00027
         		10
    Figure US20160024011A1-20160128-C00028
         		11
    Figure US20160024011A1-20160128-C00029
         		12
  • In one embodiment, the parent drug moieties (APIs), are selected from Table 2. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-2. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 2
    Figure US20160024011A1-20160128-C00030
         		1
    Figure US20160024011A1-20160128-C00031
         		2
    Figure US20160024011A1-20160128-C00032
         		3
    Figure US20160024011A1-20160128-C00033
         		4
    Figure US20160024011A1-20160128-C00034
         		5
    Figure US20160024011A1-20160128-C00035
         		6
    Figure US20160024011A1-20160128-C00036
         		7
    Figure US20160024011A1-20160128-C00037
         		8
    Figure US20160024011A1-20160128-C00038
         		9
    Figure US20160024011A1-20160128-C00039
         		10
    Figure US20160024011A1-20160128-C00040
         		11
    Figure US20160024011A1-20160128-C00041
         		12
    Figure US20160024011A1-20160128-C00042
         		13
    Figure US20160024011A1-20160128-C00043
         		14
    Figure US20160024011A1-20160128-C00044
         		15
    Figure US20160024011A1-20160128-C00045
         		16
    Figure US20160024011A1-20160128-C00046
         		17
    Figure US20160024011A1-20160128-C00047
         		18
    Figure US20160024011A1-20160128-C00048
         		19
    Figure US20160024011A1-20160128-C00049
         		20
    Figure US20160024011A1-20160128-C00050
         		21
    Figure US20160024011A1-20160128-C00051
         		22
    Figure US20160024011A1-20160128-C00052
         		23
    Figure US20160024011A1-20160128-C00053
         		24
    Figure US20160024011A1-20160128-C00054
         		25
    Figure US20160024011A1-20160128-C00055
         		26
    Figure US20160024011A1-20160128-C00056
         		27
    Figure US20160024011A1-20160128-C00057
         		28
    Figure US20160024011A1-20160128-C00058
         		29
    Figure US20160024011A1-20160128-C00059
         		30
    Figure US20160024011A1-20160128-C00060
         		31
    Figure US20160024011A1-20160128-C00061
         		32
    Figure US20160024011A1-20160128-C00062
         		33
    Figure US20160024011A1-20160128-C00063
         		34
    Figure US20160024011A1-20160128-C00064
         		35
    Figure US20160024011A1-20160128-C00065
         		36
    Figure US20160024011A1-20160128-C00066
         		37
    Figure US20160024011A1-20160128-C00067
         		38
    Figure US20160024011A1-20160128-C00068
         		39
    Figure US20160024011A1-20160128-C00069
         		40
    Figure US20160024011A1-20160128-C00070
         		41
    Figure US20160024011A1-20160128-C00071
         		42
    Figure US20160024011A1-20160128-C00072
         		43
    Figure US20160024011A1-20160128-C00073
         		44
    Figure US20160024011A1-20160128-C00074
         		45
    Figure US20160024011A1-20160128-C00075
         		46
    Figure US20160024011A1-20160128-C00076
         		47
    Figure US20160024011A1-20160128-C00077
         		48
    Figure US20160024011A1-20160128-C00078
         		49
    Figure US20160024011A1-20160128-C00079
         		50
    Figure US20160024011A1-20160128-C00080
         		51
    Figure US20160024011A1-20160128-C00081
         		52
    Figure US20160024011A1-20160128-C00082
         		53
    Figure US20160024011A1-20160128-C00083
         		53
    Figure US20160024011A1-20160128-C00084
         		54
  • In one embodiment, the parent drug moieties (APIs) are selected from Table 3. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table 3. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 3
    Figure US20160024011A1-20160128-C00085
         		1
    Figure US20160024011A1-20160128-C00086
         		2
    Figure US20160024011A1-20160128-C00087
         		3
    Figure US20160024011A1-20160128-C00088
         		4
    Figure US20160024011A1-20160128-C00089
         		5
    Figure US20160024011A1-20160128-C00090
         		6
    Figure US20160024011A1-20160128-C00091
         		7
    Figure US20160024011A1-20160128-C00092
         		8
    Figure US20160024011A1-20160128-C00093
         		9
    Figure US20160024011A1-20160128-C00094
         		10
    Figure US20160024011A1-20160128-C00095
         		11
    Figure US20160024011A1-20160128-C00096
         		12
    Figure US20160024011A1-20160128-C00097
         		13
    Figure US20160024011A1-20160128-C00098
         		14
    Figure US20160024011A1-20160128-C00099
         		15
    Figure US20160024011A1-20160128-C00100
         		16
    Figure US20160024011A1-20160128-C00101
         		17
    Figure US20160024011A1-20160128-C00102
         		18
    Figure US20160024011A1-20160128-C00103
         		19
    Figure US20160024011A1-20160128-C00104
         		20
    • Prodrugs of Acylanilines
  • In one embodiment, the compounds suitable for use in the methods of the invention are derivatives of acylaniline-, -containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • In one embodiment, compounds of the present invention are represented by Formula III below, or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof:
  • Figure US20160024011A1-20160128-C00105
  • wherein each R50, R51, R52, R53, R54 and R55 is independently selected from hydrogen, halogen, —OR10, —SR10, —NR10R11—, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; alternatively, two or more R50, R51, R52, R53, R54 and R55 together form an optionally substituted ring.
  • In one embodiment, the parent drug moieties (APIs), are selected from Table 4. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are independently selected from Table-4. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 4
    Figure US20160024011A1-20160128-C00106
         		1
    Figure US20160024011A1-20160128-C00107
         		2
    Figure US20160024011A1-20160128-C00108
         		3
    Figure US20160024011A1-20160128-C00109
         		4
    Figure US20160024011A1-20160128-C00110
         		5
    Figure US20160024011A1-20160128-C00111
         		6
    Figure US20160024011A1-20160128-C00112
         		7
    Figure US20160024011A1-20160128-C00113
         		8
    Figure US20160024011A1-20160128-C00114
         		9
    Figure US20160024011A1-20160128-C00115
         		10
    Figure US20160024011A1-20160128-C00116
         		11
    Figure US20160024011A1-20160128-C00117
         		12
    Figure US20160024011A1-20160128-C00118
         		13
    Figure US20160024011A1-20160128-C00119
         		14
    Figure US20160024011A1-20160128-C00120
         		15
    Figure US20160024011A1-20160128-C00121
         		16
    Figure US20160024011A1-20160128-C00122
         		17
    Figure US20160024011A1-20160128-C00123
         		18
    Figure US20160024011A1-20160128-C00124
         		19
    Figure US20160024011A1-20160128-C00125
         		20
    Figure US20160024011A1-20160128-C00126
         		21
    Figure US20160024011A1-20160128-C00127
         		22
    Figure US20160024011A1-20160128-C00128
         		23
    Figure US20160024011A1-20160128-C00129
         		24
    Figure US20160024011A1-20160128-C00130
         		25
    Figure US20160024011A1-20160128-C00131
         		26
    Figure US20160024011A1-20160128-C00132
         		27
    Figure US20160024011A1-20160128-C00133
         		28
    Figure US20160024011A1-20160128-C00134
         		29
    Figure US20160024011A1-20160128-C00135
         		30
    Figure US20160024011A1-20160128-C00136
         		31
    Figure US20160024011A1-20160128-C00137
         		32
    Figure US20160024011A1-20160128-C00138
         		33
    Figure US20160024011A1-20160128-C00139
         		34
    Figure US20160024011A1-20160128-C00140
         		35
    Figure US20160024011A1-20160128-C00141
         		36
    Figure US20160024011A1-20160128-C00142
         		37
    Figure US20160024011A1-20160128-C00143
         		38
    Figure US20160024011A1-20160128-C00144
         		39
    Figure US20160024011A1-20160128-C00145
         		40
    Figure US20160024011A1-20160128-C00146
         		41
    Figure US20160024011A1-20160128-C00147
         		42
    Figure US20160024011A1-20160128-C00148
         		43
    Figure US20160024011A1-20160128-C00149
         		44
    Figure US20160024011A1-20160128-C00150
         		45
    Figure US20160024011A1-20160128-C00151
         		46
    Figure US20160024011A1-20160128-C00152
         		47
    Figure US20160024011A1-20160128-C00153
         		48
    Figure US20160024011A1-20160128-C00154
         		49
    Figure US20160024011A1-20160128-C00155
         		50
    Figure US20160024011A1-20160128-C00156
         		51
    Figure US20160024011A1-20160128-C00157
         		52
    Figure US20160024011A1-20160128-C00158
         		53
    Figure US20160024011A1-20160128-C00159
         		54
    Figure US20160024011A1-20160128-C00160
         		55
    Figure US20160024011A1-20160128-C00161
         		56
    Figure US20160024011A1-20160128-C00162
         		57
    Figure US20160024011A1-20160128-C00163
         		58
    Figure US20160024011A1-20160128-C00164
         		59
    Figure US20160024011A1-20160128-C00165
         		60
    Figure US20160024011A1-20160128-C00166
         		61
    Figure US20160024011A1-20160128-C00167
         		62
    Figure US20160024011A1-20160128-C00168
         		63
    Figure US20160024011A1-20160128-C00169
         		64
    Figure US20160024011A1-20160128-C00170
         		65
    Figure US20160024011A1-20160128-C00171
         		66
    Figure US20160024011A1-20160128-C00172
         		67
    Figure US20160024011A1-20160128-C00173
         		68
    Figure US20160024011A1-20160128-C00174
         		69
    Figure US20160024011A1-20160128-C00175
         		70
    Figure US20160024011A1-20160128-C00176
         		71
    Figure US20160024011A1-20160128-C00177
         		72
    Figure US20160024011A1-20160128-C00178
         		73
    Figure US20160024011A1-20160128-C00179
         		74
    Figure US20160024011A1-20160128-C00180
         		75
    Figure US20160024011A1-20160128-C00181
         		76
    Figure US20160024011A1-20160128-C00182
         		77
    Figure US20160024011A1-20160128-C00183
         		78
    • Thiazolidinones
  • In one embodiment, the compounds suitable for use in the methods of the invention are derivatives of thioazolidine-, -containing parent drugs that are substituted at an amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • In one embodiment, compounds of the present invention are represented by Formula IV below, or its geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof:
  • Figure US20160024011A1-20160128-C00184
  • wherein Cy2 is an optionally substituted heterocyclic ring; and X5 is selected from absent, —S—, —O—, —S(O)—, —S(O)2—, —N(R10)—, —C(O)—, —C(OR10)(R11)—, —[C(R10)(R11)]v—, —O[C(R10)(R11)]v—, —O[C(R10)(R11)]vO—, —S[C(R10)(R11)]vO—, —NR12[C(R10)(R11)]vO—, —NR12[C(R10)(R11)]vS—, —S[C(R10)(R11)]v—, —C(O)[C(R10)(R11)]v—, and —C(R10)(R11)═C(R10)(R11)—; wherein v is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • In one embodiment, the parent drug moieties (APIs), are independently selected from Table 5. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-5. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 5
    Figure US20160024011A1-20160128-C00185
         		1
    Figure US20160024011A1-20160128-C00186
         		2
    Figure US20160024011A1-20160128-C00187
         		3
    Figure US20160024011A1-20160128-C00188
         		4
    Figure US20160024011A1-20160128-C00189
         		5
    Figure US20160024011A1-20160128-C00190
         		6
    Figure US20160024011A1-20160128-C00191
         		7
    Figure US20160024011A1-20160128-C00192
         		8
    Figure US20160024011A1-20160128-C00193
         		9
    Figure US20160024011A1-20160128-C00194
         		10
    Figure US20160024011A1-20160128-C00195
         		11
    Figure US20160024011A1-20160128-C00196
         		12
    Figure US20160024011A1-20160128-C00197
         		13
    Figure US20160024011A1-20160128-C00198
         		14
    Figure US20160024011A1-20160128-C00199
         		15
    Figure US20160024011A1-20160128-C00200
         		16
    Figure US20160024011A1-20160128-C00201
         		17
    Figure US20160024011A1-20160128-C00202
         		18
    Figure US20160024011A1-20160128-C00203
         		19
    Figure US20160024011A1-20160128-C00204
         		20
    Figure US20160024011A1-20160128-C00205
         		21
    • Barbiturates
  • In one embodiment, the compounds suitable for use in the methods of the invention are derivatives of barbiturates that are substituted at an amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • In one embodiment, the parent drug moieties (APIs), are selected from Table 6. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-6. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 6
    Figure US20160024011A1-20160128-C00206
         		1
    Figure US20160024011A1-20160128-C00207
         		2
    Figure US20160024011A1-20160128-C00208
         		3
    Figure US20160024011A1-20160128-C00209
         		4
    Figure US20160024011A1-20160128-C00210
         		5
    Figure US20160024011A1-20160128-C00211
         		6
    Figure US20160024011A1-20160128-C00212
         		7
    Figure US20160024011A1-20160128-C00213
         		8
    Figure US20160024011A1-20160128-C00214
         		9
    Figure US20160024011A1-20160128-C00215
         		10
    Figure US20160024011A1-20160128-C00216
         		11
    Figure US20160024011A1-20160128-C00217
         		12
    Figure US20160024011A1-20160128-C00218
         		13
    Figure US20160024011A1-20160128-C00219
         		14
    Figure US20160024011A1-20160128-C00220
         		15
    Figure US20160024011A1-20160128-C00221
         		16

    wherein M is a pharmaceutically acceptable cation.
    • Prodrugs of Pyridone and Pyrimidine Containing Parent Drugs
  • In one embodiment, the compounds suitable for use in the methods of the invention are derivatives of pyridine and pyrimidine containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • In one embodiment, the parent drug moieties (APIs), are selected from Table 7. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-7. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 7
    Figure US20160024011A1-20160128-C00222
         		1
    Figure US20160024011A1-20160128-C00223
         		2
    Figure US20160024011A1-20160128-C00224
         		3
    Figure US20160024011A1-20160128-C00225
         		4
    Figure US20160024011A1-20160128-C00226
         		5
    Figure US20160024011A1-20160128-C00227
         		6
    Figure US20160024011A1-20160128-C00228
         		7
    Figure US20160024011A1-20160128-C00229
         		8
    Figure US20160024011A1-20160128-C00230
         		9
    Figure US20160024011A1-20160128-C00231
         		10
    Figure US20160024011A1-20160128-C00232
         		11
    Figure US20160024011A1-20160128-C00233
         		12
    Figure US20160024011A1-20160128-C00234
         		13
    Figure US20160024011A1-20160128-C00235
         		14
    Figure US20160024011A1-20160128-C00236
         		15
    Figure US20160024011A1-20160128-C00237
         		16
    • Prodrugs of Benzamide Parent Drugs
  • In one embodiment, the compounds suitable for use in the methods of the invention are derivatives of benzamide containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • In one embodiment, the parent drug moieties (APIs) are independently selected from Table 8. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-8. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 8
    Figure US20160024011A1-20160128-C00238
         		1
    Figure US20160024011A1-20160128-C00239
         		2
    Figure US20160024011A1-20160128-C00240
         		3
    Figure US20160024011A1-20160128-C00241
         		4
    Figure US20160024011A1-20160128-C00242
         		5
    Figure US20160024011A1-20160128-C00243
         		6
    Figure US20160024011A1-20160128-C00244
         		7
    Figure US20160024011A1-20160128-C00245
         		8
    Figure US20160024011A1-20160128-C00246
         		9
    Figure US20160024011A1-20160128-C00247
         		10
    Figure US20160024011A1-20160128-C00248
         		11
    Figure US20160024011A1-20160128-C00249
         		12
    Figure US20160024011A1-20160128-C00250
         		13
    Figure US20160024011A1-20160128-C00251
         		14
    Figure US20160024011A1-20160128-C00252
         		15
    Figure US20160024011A1-20160128-C00253
         		16
    Figure US20160024011A1-20160128-C00254
         		17
    Figure US20160024011A1-20160128-C00255
         		18
    Figure US20160024011A1-20160128-C00256
         		19
    Figure US20160024011A1-20160128-C00257
         		20
    Figure US20160024011A1-20160128-C00258
         		21
    Figure US20160024011A1-20160128-C00259
         		22
    Figure US20160024011A1-20160128-C00260
         		23
    Figure US20160024011A1-20160128-C00261
         		24
    Figure US20160024011A1-20160128-C00262
         		25
    Figure US20160024011A1-20160128-C00263
         		26
    Figure US20160024011A1-20160128-C00264
         		27
    Figure US20160024011A1-20160128-C00265
         		28
    Figure US20160024011A1-20160128-C00266
         		29
    Figure US20160024011A1-20160128-C00267
         		30
    Figure US20160024011A1-20160128-C00268
         		31
    Figure US20160024011A1-20160128-C00269
         		32
    Figure US20160024011A1-20160128-C00270
         		33
    Figure US20160024011A1-20160128-C00271
         		34
    Figure US20160024011A1-20160128-C00272
         		35
    Figure US20160024011A1-20160128-C00273
         		36
    Figure US20160024011A1-20160128-C00274
         		37
    Figure US20160024011A1-20160128-C00275
         		38
    Figure US20160024011A1-20160128-C00276
         		39
    Figure US20160024011A1-20160128-C00277
         		40
    Figure US20160024011A1-20160128-C00278
         		41
    Figure US20160024011A1-20160128-C00279
         		42
    • Prodrugs of Imide Containing Parent Drugs
  • In one embodiment, the compounds suitable for use in the methods of the invention are derivatives of imide containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • In one embodiment, the parent drug moieties (APIs) are independently selected from Table 9. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-9. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 9
    Figure US20160024011A1-20160128-C00280
         		1.
    Figure US20160024011A1-20160128-C00281
         		2.
    Figure US20160024011A1-20160128-C00282
         		3.
    Figure US20160024011A1-20160128-C00283
         		4.
    Figure US20160024011A1-20160128-C00284
         		5.
    Figure US20160024011A1-20160128-C00285
         		6.
    Figure US20160024011A1-20160128-C00286
         		7.
    Figure US20160024011A1-20160128-C00287
         		8.
    Figure US20160024011A1-20160128-C00288
         		9.
    Figure US20160024011A1-20160128-C00289
         		10.
    Figure US20160024011A1-20160128-C00290
         		11.
    Figure US20160024011A1-20160128-C00291
         		12.
    Figure US20160024011A1-20160128-C00292
         		13.
    Figure US20160024011A1-20160128-C00293
         		14.
    Figure US20160024011A1-20160128-C00294
         		15.
    Figure US20160024011A1-20160128-C00295
         		16.
    Figure US20160024011A1-20160128-C00296
         		17.
    Figure US20160024011A1-20160128-C00297
         		18.
    Figure US20160024011A1-20160128-C00298
         		19.
    Figure US20160024011A1-20160128-C00299
         		20.
    Figure US20160024011A1-20160128-C00300
         		21.
    Figure US20160024011A1-20160128-C00301
         		22.
    Figure US20160024011A1-20160128-C00302
         		23.
    Figure US20160024011A1-20160128-C00303
         		24.
    Figure US20160024011A1-20160128-C00304
         		25.
    Figure US20160024011A1-20160128-C00305
         		26.
    Figure US20160024011A1-20160128-C00306
         		27.
    Figure US20160024011A1-20160128-C00307
         		28.
    Figure US20160024011A1-20160128-C00308
         		29.
    Figure US20160024011A1-20160128-C00309
         		30.
    Figure US20160024011A1-20160128-C00310
         		31.
    Figure US20160024011A1-20160128-C00311
         		32.
    Figure US20160024011A1-20160128-C00312
         		33.
    Figure US20160024011A1-20160128-C00313
         		34.
    Figure US20160024011A1-20160128-C00314
         		35.
    Figure US20160024011A1-20160128-C00315
         		36.
    Figure US20160024011A1-20160128-C00316
         		37.
    Figure US20160024011A1-20160128-C00317
         		38.
    Figure US20160024011A1-20160128-C00318
         		39.
    Figure US20160024011A1-20160128-C00319
         		40.
    Figure US20160024011A1-20160128-C00320
         		41.
    Figure US20160024011A1-20160128-C00321
         		42.
    Figure US20160024011A1-20160128-C00322
         		43.
    Figure US20160024011A1-20160128-C00323
         		44.
    Figure US20160024011A1-20160128-C00324
         		45.
    Figure US20160024011A1-20160128-C00325
         		46.
    Figure US20160024011A1-20160128-C00326
         		47.
    Figure US20160024011A1-20160128-C00327
         		48.
    • Prodrugs of Cyclic Ureas
  • In one embodiment, the compounds suitable for use in the methods of the invention are derivatives of cyclic urea-containing parent drugs that are substituted at either of the urea nitrogens or oxygen with labile aldehyde-linked prodrug moieties.
  • In one embodiment, the parent drug moieties (APIs), are independently selected from Table 10. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-10. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 10
    No Structure
     1
    Figure US20160024011A1-20160128-C00328
     2
    Figure US20160024011A1-20160128-C00329
     3
    Figure US20160024011A1-20160128-C00330
     4
    Figure US20160024011A1-20160128-C00331
     5
    Figure US20160024011A1-20160128-C00332
     6
    Figure US20160024011A1-20160128-C00333
     7
    Figure US20160024011A1-20160128-C00334
     8
    Figure US20160024011A1-20160128-C00335
     9
    Figure US20160024011A1-20160128-C00336
    10
    Figure US20160024011A1-20160128-C00337
    11
    Figure US20160024011A1-20160128-C00338
    12
    Figure US20160024011A1-20160128-C00339
    13
    Figure US20160024011A1-20160128-C00340
    14
    Figure US20160024011A1-20160128-C00341
    • Prodrugs of Sulfonamide Parent Drugs
  • In one embodiment, the compounds suitable for use in the methods of the invention are derivatives of sulfonamide parent drugs that are substituted at the sulfonamide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties.
  • Figure US20160024011A1-20160128-C00342
  • wherein A and B together with the sulfonamide group forms the parent drug; and, A2 and B2 together with the sulfonamide group form the parent drug.
  • In one embodiment, the parent drug moieties (APIs), are selected from Table 11. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are independently selected from Table-11. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 11
    Figure US20160024011A1-20160128-C00343
         		1
    Figure US20160024011A1-20160128-C00344
         		2
    Figure US20160024011A1-20160128-C00345
         		3
    Figure US20160024011A1-20160128-C00346
         		4
    Figure US20160024011A1-20160128-C00347
         		5
    Figure US20160024011A1-20160128-C00348
         		6
    Figure US20160024011A1-20160128-C00349
         		7
    Figure US20160024011A1-20160128-C00350
         		8
    Figure US20160024011A1-20160128-C00351
         		9
    Figure US20160024011A1-20160128-C00352
         		10
    Figure US20160024011A1-20160128-C00353
         		11
    Figure US20160024011A1-20160128-C00354
         		12
    Figure US20160024011A1-20160128-C00355
         		13
    Figure US20160024011A1-20160128-C00356
         		14
    Figure US20160024011A1-20160128-C00357
         		15
    Figure US20160024011A1-20160128-C00358
         		16
    Figure US20160024011A1-20160128-C00359
         		17
    Figure US20160024011A1-20160128-C00360
         		18
    Figure US20160024011A1-20160128-C00361
         		19
    Figure US20160024011A1-20160128-C00362
         		20
    Figure US20160024011A1-20160128-C00363
         		21
    Figure US20160024011A1-20160128-C00364
         		22
    Figure US20160024011A1-20160128-C00365
         		23
    Figure US20160024011A1-20160128-C00366
         		24
    Figure US20160024011A1-20160128-C00367
         		25
    Figure US20160024011A1-20160128-C00368
         		26
    Figure US20160024011A1-20160128-C00369
         		27
    Figure US20160024011A1-20160128-C00370
         		28
    Figure US20160024011A1-20160128-C00371
         		29
    Figure US20160024011A1-20160128-C00372
         		30
    Figure US20160024011A1-20160128-C00373
         		31
    Figure US20160024011A1-20160128-C00374
         		32
    Figure US20160024011A1-20160128-C00375
         		33
    Figure US20160024011A1-20160128-C00376
         		34
    Figure US20160024011A1-20160128-C00377
         		35
    Figure US20160024011A1-20160128-C00378
         		36
    Figure US20160024011A1-20160128-C00379
         		37
    Figure US20160024011A1-20160128-C00380
         		38
    Figure US20160024011A1-20160128-C00381
         		39
    Figure US20160024011A1-20160128-C00382
         		40
    Figure US20160024011A1-20160128-C00383
         		41
    Figure US20160024011A1-20160128-C00384
         		42
    Figure US20160024011A1-20160128-C00385
         		43
    Figure US20160024011A1-20160128-C00386
         		44
    Figure US20160024011A1-20160128-C00387
         		45
    Figure US20160024011A1-20160128-C00388
         		46
    Figure US20160024011A1-20160128-C00389
         		47
    Figure US20160024011A1-20160128-C00390
         		48
    Figure US20160024011A1-20160128-C00391
         		49
    Figure US20160024011A1-20160128-C00392
         		50
    Figure US20160024011A1-20160128-C00393
         		51
    Figure US20160024011A1-20160128-C00394
         		52
    Figure US20160024011A1-20160128-C00395
         		53
    Figure US20160024011A1-20160128-C00396
         		54
    Figure US20160024011A1-20160128-C00397
         		55
    Figure US20160024011A1-20160128-C00398
         		56
    Figure US20160024011A1-20160128-C00399
         		57
    Figure US20160024011A1-20160128-C00400
         		58
    Figure US20160024011A1-20160128-C00401
         		59
    Figure US20160024011A1-20160128-C00402
         		60
    Figure US20160024011A1-20160128-C00403
         		61
    Figure US20160024011A1-20160128-C00404
         		62
    Figure US20160024011A1-20160128-C00405
         		63
    Figure US20160024011A1-20160128-C00406
         		64
    Figure US20160024011A1-20160128-C00407
         		65
    Figure US20160024011A1-20160128-C00408
         		66
    Figure US20160024011A1-20160128-C00409
         		67
    Figure US20160024011A1-20160128-C00410
         		68
    Figure US20160024011A1-20160128-C00411
         		69
    Figure US20160024011A1-20160128-C00412
         		70
    Figure US20160024011A1-20160128-C00413
         		71
    Figure US20160024011A1-20160128-C00414
         		72
    • Prodrugs of Tertiary Amine Containing Parent Drugs
  • In some embodiments, the invention relates to a prodrug conjugates having the Formula V:
  • Figure US20160024011A1-20160128-C00415
  • wherein A1, B1 and E1 together with the nitrogen they are attached to form a tertiary amine containing first biologically active molecule;
    A2, B2 and E2 together with the nitrogen they are attached to form a tertiary amine containing second biologically active molecule;
    X1 is selected from O or S;
    X2 is selected from direct bond, O, S or NR20 wherein R20 is selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl;
    X— is a pharmaceutically acceptable counterion; and,
    C1 represents a carrier moiety.
  • In some embodiments, the invention relates to a prodrug conjugates having the Formula VI:
  • Figure US20160024011A1-20160128-C00416
  • wherein n is an integer between 1 and 50;
    n, A1, E1, B1, A2, E2, B2, X1, X2, R10, R11 and X— are as defined above.
  • In some embodiments, n is selected from 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30.
  • In some embodiments, the invention relates to a prodrug conjugates having the Formula VII:
  • Figure US20160024011A1-20160128-C00417
  • n, A1, B1, A2, E2, B2, X1, X2, and X— are as defined above.
  • The tertiary amine-containing parent drug may be any tertiary amine-containing drug that induces a desired local or systemic effect. Such drugs include broad classes of compounds. In general, this includes: analgesic agents; anesthetic agents; antiarthritic agents; respiratory drugs, including antiasthmatic agents; anticancer agents, including antineoplastic agents; anticholinergics; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihelminthics; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents such as antibiotics and antiviral agents; antiinflammatory agents; antimigraine preparations; antinauseants; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antitubercular agents; antiulcer agents; antiviral agents; anxiolytics; appetite suppressants; attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) drugs; cardiovascular preparations including calcium channel blockers, CNS agents; beta-blockers and antiarrhythmic agents; central nervous system stimulants; cough and cold preparations, including decongestants; diuretics; genetic materials; gastrointestinal (GI) motility agents; herbal remedies; hormones; hormonolytics; hypnotics; hypoglycemic agents; immunosuppressive agents; leukotriene inhibitors; mitotic inhibitors; muscle relaxants; narcotic antagonists; nicotine; nutritional agents, such as vitamins, essential amino acids and fatty acids; ophthalmic drugs such as antiglaucoma agents; parasympatholytics; peptide drugs; psychostimulants; sedatives; steroids; sympathomimetics; tranquilizers; and vasodilators including general coronary, peripheral and cerebral.
  • Examples of tertiary amine-containing antibiotic parent drugs from which the prodrugs of the invention may be derived include: clindamycin, ofloxacin/levofloxacin, pefloxacin, quinupristine, rolitetracycline, and cefotiam.
  • Examples of tertiary amine-containing antifungal parent drugs from which the prodrugs of the invention may be derived include: butenafine, naftifine, and terbinafine.
  • Examples of tertiary amine-containing antimalarials and antiprotozoals parent drugs from which the prodrugs of the invention may be derived include: amodiaquine, quinacrine, sitamaquine, quinine.
  • Examples of tertiary amine-containing HIV protease inhibitor parent drugs from which the prodrugs of the invention may be derived include: saquinavir, indinavir, atazanavir and nelfinavir. Anti-HIV drugs also include maraviroc and aplaviroc for inhibition of HIV entry.
  • Examples of tertiary amine-containing anticonvulsants/antispasmodics parent drugs from which the prodrugs of the invention may be derived include: atropine, darifenancin; dicyclomine; hyoscayamine, tiagabine, flavoxate; and alverine.
  • Examples of tertiary-amine containing antidepressant parent drugs from which the prodrugs of the invention are derived include: amitriptyline, adinazolam, citalopram, cotinine, clomipramine, doxepin, escitalopram, femoxetine, imipramine, minaprine, moclobemide, mianserin, mirtazapine, nefazodone, nefopam, pipofenazine, promazine, ritanserin, trazodone, trimipramine and venlafaxine.
  • Examples of tertiary amine-containing antiemetic parent drugs from which the prodrugs of the invention are derived include: aprepitant, buclizine, cilansetron, cyclizine, dolasetron, granisetron, meclizine, ondansetron, palonosetron, ramosetron, thiethylperazine, trimethobenzamide, scopolamine, and prochlorperazine.
  • Examples of tertiary amine-containing antihistamine parent drugs from which the prodrugs of the invention are derived include: acetprometazine, azatadine, azelastine, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, dexobrompheniramine, diphenhydramine, diphenylpyraline, doxepin, emadastine, loratadine, mequitazine, olopatadine, phenindamine, pheniramine, promethazine, tripelennamine, triprolidine, astemizole, cetirizine, fexofenadine, terfenadine, latrepirdine, ketotifen, cyproheptadine, hydroxyzine, clobenzepam doxylamine, cinnarizine, orphenadrine.
  • Examples of tertiary amine-containing antiparkinsonian parent drugs from which prodrugs of the invention are derived include: cabergoline, ethopropazine, pergolide, selegiline, metixene, biperiden, cycrimine, procycladine and apomorphine.
  • Examples of tertiary amine-containing antipsychotic parent drugs from which prodrugs of the invention are derived include: acetophenazine, amisulpride, aripiprazole, bifeprunox, blonanserin, cariprazine, carphenazine, clopenthixol, clozapine, dehydro aripiprazole, someperidone, droperidol, flupenthixol, fluphenazine, fluspirilene, haloperidol, iloperidone, lurasidone, mesoridazine, molindole, nemanopride, olanzapine, perospirone, perphenazine, PF-00217830 (Pfizer), pipotiazine, propericiazine, quetiapine, remoxipride, risperidone, sertindole, SLV-313 (Solvay/Wyeth), sulpiride, thioproperazine, thioridazine, thiothixene, trifluoperazine, ziprasidone, zotepine, pimozide, benzquinamide, triflupromazine, tetrabenazine, melperon, asenapine, chlorprothixene, spiperone and chlorpromazine.
  • Examples of tertiary amine-containing anxiolytic parent drugs from which prodrugs of the invention are derived include: buspirone, and loxapine.
  • Examples of tertiary amine-containing nootroopic (memory and cognitive enhancers) parent drugs from which prodrugs of the invention are derived include: donepezil, galantamine, latrepirdine, nicotine, TC-5616 (Targacept, Inc.) having the IUPAC name: N-[(2S,3S)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide.
  • Examples of tertiary amine-containing parent drugs for erectile dysfunction from which prodrugs of the invention are derived include: apomorphine and sildenafil.
  • Examples of tertiary amine-containing parent drugs for migraine headache from which prodrugs of the invention are derived include: almotriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergotamine, ergotamine, eletripan and lisuride.
  • Examples of tertiary amine-containing parent drugs for the treatment of alcoholism from which prodrugs of the invention are derived include: naloxone and naltrexone. Other narcotic antagonist amine containing parent drugs for treatment of substance abuse from which prodrugs of the invention are derived include: levallorphan, nalbuphine, nalorphine and nalmefene.
  • Examples of a tertiary amine-containing parent drug for the treatment of addiction from which a prodrug of the invention is derived include: buprenorphine, isomethadone, levomethadyl acetate, methadyl acetate, nor-acetyl levomethadol, and normethadone.
  • Examples of tertiary amine-containing muscle relaxant parent drugs from which prodrugs are derived include: cyclobenzaprine, nefopam, tolperisone, orphenadrine, and quinine.
  • Examples of tertiary amine-containing nonsteroidal anti-inflammatory parent drugs from which prodrugs of the invention are derived include: etodolac, meloxicam, ketorolac, lornoxicam and tenoxicam. Examples of tertiary amine-containing opioid parent drugs from which prodrugs of the invention are derived include alfentanil, anileridine, buprenorphine, butorphanol, clonitazene, codeine, dihydrocodeine, dihydromorphin, fentanyl, hydromorphone, meperidine, metazocine, methadone, morphine, oxycodone, hyrdocodone, oxymorphone, pentazocine, remifentanil, and sufentanil.
  • Examples of other tertiary amine-containing analgesic parent drugs from which prodrugs of the invention are derived include: methotrimeprazine, tramadol, nefopam, phenazocine, propiram, quinupramine, thebaine and propoxyphene.
  • Examples of tertiary amine-containing sedatives/hypnotics from which the prodrugs of the invention may be derived include: eszopiclone, flurazepam, propiomazine, and zopiclone.
  • Examples of tertiary amine-containing local analgesic parent drugs from which prodrugs of the invention are derived include: bupivacaine, dexmedetomidine, dibucaine, dyclonine, lodicaine, mepivacaine, procaine, and tapentadol and ropivacaine.
  • Examples of tertiary amine-containing antianginals from which the prodrugs of the invention may be derived include: ranozaline, bepridil.
  • Examples of tertiary amine-containing antiarrhythmics from which the prodrugs of the invention may be derived include: amiodarone, aprindine, encainide, moricizine, procainamide, diltiazem, verapamil, bepridil.
  • Examples of tertiary amine-containing antihypertensives from which the prodrugs of the invention may be derived include: azelnidipine, deserpidine, ketanserin, reserpine, and sildenafil.
  • Examples of tertiary amine-containing antithrombotics from which the prodrugs of the invention may be derived include: clopidogrel and ticlopidine.
  • Examples of tertiary amine-containing antineoplastic parent drugs from which prodrugs of the invention are derived include: dasatinib, flavopiridol, gefitinib, imatinib, sunitinib, topotecan, vinblastine, vincristine, fincesine, vinorelbine, vinorelbine, tamoxifen, tremifene, and tesmilifene.
  • Examples of tertiary amine-containing drugs parent drugs for use in treating irritable bowel syndrome (IBS) from which the prodrugs of the invention are derived include asimadoline.
  • Examples of other tertiary amine-containing parent drugs from which the prodrugs of the invention are derived include: antimuscarinics and anticholinergics such as benzotropine, procyclidine and trihexylphanidyl; alpha andrenergic blockers such as dapiprazole, dexmedetomidine and nicergoline; anorexics such as diethylpropian, benzapehtamine, phendimetrazine, and sibutramine; antidiarrhels such as diphenoxylate and loperamide, antikinetic and antihypertensives such as clonidine; antiosteoporotics such as raloxifene; antipruritics such as methyldilazine; antitussives such as dextromethorphan; antiulceratives such as pirenzepine; cholinesterase inhibitors such as galantamine; gastroprokinetics such as alvimopan, cisapride, and piboserod; miglustat for treating glycosphingolipid lysosomal storage disorder; clomifene as gonad stimulating prinicipal; neuromuscular blockers such as dihydro-beta-erythrodoidine, niotropics such as rivastigmine, oxytocics such as methylergonovine; antiametics such as chloroquine; respiratory stimulants such as doxapram; muscarinic receptor antagonists for treating urinary incontinence such as oxybutynin and solifenacin; calcium channel blockers such as flunarizine; anthelmintics such as diethylcarbamazine and quinacrine; miotics such as physostigmine; neuroprotectives such as lubeluzole; immunosuppressants such as mycophenolate mofetil; and stimulants such as nicotine.
  • Preferred tertiary amine-containing parent drugs from which prodrugs of the invention are derived include: amisulpride, aripiprazole, asenapine, cariprazine, citalopram, dehydroaripiprazole, escitalopram, galantamine, iloperidone, latrepirdine, olanzapine, paliperidone, perospirone, risperidone, and ziprasidone.
  • The present invention is intended to encompass any parent drug compound or any substituted parent drug compound which contains a tertiary amine group and which is biologically active and can be derivatized according to the present invention to afford the corresponding prodrugs. While the tertiary amine-containing parent drugs from which the prodrugs of the invention may be derived are numerous, many of the chemical structures of the prodrugs of the invention can be characterized by certain general structure types. One type includes those wherein the tertiary amine nitrogen is part of a cyclic (including bicyclic or tricyclic) aliphatic group such as piperidine, piperazine, morpholine, pyrrolidine, azapine, and diazapine. Another type includes those wherein the tertiary amine nitrogen is part of an alkyl amine group such as a diethyl and/or dimethyl amine.
  • In some embodiments, the invention relates to a prodrug conjugates having the Formula VIII:
  • Figure US20160024011A1-20160128-C00418
  • wherein A— is a pharmaceutically acceptable counterion; and X1, and X2, are as defined above.
  • In one embodiment, the parent drug moieties (APIs) are independently selected from Table 12. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table-12. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 12
    Figure US20160024011A1-20160128-C00419
    Figure US20160024011A1-20160128-C00420
    Figure US20160024011A1-20160128-C00421
    Figure US20160024011A1-20160128-C00422
    Figure US20160024011A1-20160128-C00423
    Figure US20160024011A1-20160128-C00424
    Figure US20160024011A1-20160128-C00425
    Figure US20160024011A1-20160128-C00426
    Figure US20160024011A1-20160128-C00427
    Figure US20160024011A1-20160128-C00428
    Figure US20160024011A1-20160128-C00429
    Figure US20160024011A1-20160128-C00430
    Figure US20160024011A1-20160128-C00431
    Figure US20160024011A1-20160128-C00432
    Figure US20160024011A1-20160128-C00433
    Figure US20160024011A1-20160128-C00434
    Figure US20160024011A1-20160128-C00435
    Figure US20160024011A1-20160128-C00436
    Figure US20160024011A1-20160128-C00437
    Figure US20160024011A1-20160128-C00438
    Figure US20160024011A1-20160128-C00439
    Figure US20160024011A1-20160128-C00440
    Figure US20160024011A1-20160128-C00441
    Figure US20160024011A1-20160128-C00442
    Figure US20160024011A1-20160128-C00443
    • Prodrugs of Heteroaryl Parent Drugs
  • In one embodiment, the compounds suitable for use in the methods of the invention are derivatives of heteroaryl NH-containing parent drugs that are substituted at the NH nitrogen atom with labile prodrug moieties. Preferably, the prodrug moieties are hydrophobic and reduce the solubility at physiological pH (pH 7.0), as well as modulate polarity and lipophilicity parameters of the prodrug as compared to the parent drug.
  • In one embodiment, the invention provides a prodrug compound of Formula IX:
  • Figure US20160024011A1-20160128-C00444
  • or a pharmaceutically acceptable salt thereof, wherein each of X10 to X17 is independently N or CR, provided that at least one of X10-X17 is CR. The R groups combine to form the portion of the prodrug compound in addition to the five-membered heteroaromatic ring. For example, the R groups can be independently hydrogen, optionally substituted aliphatic, aromatic, heteroaromatic or a combination thereof. The R groups can also be taken together with the carbon atoms to which they are attached to form one or more optionally substituted fused ring systems.
  • In a preferred embodiment, the invention relates to a prodrug conjugate of Formula X:
  • Figure US20160024011A1-20160128-C00445
  • wherein, n, X10-X17, X1, X2, R10, and R11 are as defined above.
  • Heteroaromatic NH-containing parent drugs include broad classes of compounds. In general, this includes: analgesic agents; anesthetic agents; antiarthritic agents; respiratory drugs, including antiasthmatic agents; anticancer agents, including antineoplastic agents; anticholinergics; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihelminthics; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents such as antibiotics and antiviral agents; antiinflammatory agents; antimigraine preparations; antinauseants; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antitubercular agents; antiulcer agents; antiviral agents; anxiolytics; appetite suppressants; attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) drugs; cardiovascular preparations including calcium channel blockers, CNS agents; beta-blockers and antiarrhythmic agents; central nervous system stimulants; nootropics; cough and cold preparations, including decongestants; diuretics; genetic materials; herbal remedies; hormonolytics; hypnotics; hypoglycemic agents; immunosuppressive agents; leukotriene inhibitors; mitotic inhibitors; muscle relaxants; narcotic antagonists; opioid agonists; nicotine; nutritional agents, such as vitamins, essential amino acids and fatty acids; ophthalmic drugs such as antiglaucoma agents; parasympatholytics; peptide drugs; psychostimulants; sedatives; steroids; sympathomimetics; tranquilizers; and vasodilators including general coronary, peripheral and cerebral.
  • Specific heteroaromatic NH-containing parent drugs represent a variety of drug classes. Such drugs include tranquilizers and sedatives, such as mepiprazole and dexmedetomidine; anthelmintic agents, such as albendazole, carbendazole, cyclobendazole, mebendazole and thiabendazole; antimigraine agents, such as almotriptan, dolasetron, eletriptan, lisuride, naratriptan, rizatriptan, sumatriptan, frovatriptan, zolmitriptan and ergotamine; treatments for irritable bowel syndrome, such as alosetron; antiviral agents, such as delavirdine and atevirdine; antihypertensive agents, such as bopindolol, bucindolol, candesartan, deserpidine, mibefradil, ergoloid mesylate, indoramin, irbesartan, mepindolol, olmesartan, reserpine, rescinnamine, losartan, tasosartan, valsartan, raubasine, syrosingopine, carmoxirole and rescimetol; anti-Parkinson agents, such as cabergoline, pergolide, bromocriptine and terguride; bronchodilators, such as ambuphylline; antiulcerative agents, such as cimetidine, lansoprazole, omeprazole, pantaprozole and rabeprazole; antibacterial agents, such as cefatrizine and daptomycin; oxytocic agents, such as ergonovine and methylergonovine; analgesics, such as etodolac; antineoplastic agents, such as liarozole, pemetrexed, thiamiprine, vinblastine, vincristine, vindesine, vinorelbine, voacamine and venflunine; antidepressants, such as oxypertine, indalpine and roxindole; anti-allergic agents, such as pemirolast, tazanolast and traxanox; cardiotonic agents, such as pimobendan and sulmazole; antiasthmatics, such as pranlukast; antiemetics, such as ramosetron, tropisetron and alizapride; vasodilators, such as bendazole and tadalafil; anti-gout agents, such as allopurinol; antirheumatic agents, such as azathioprine; mydriatics, such as yohimbine; therapies for congestive heart failure, such as conivaptan; and hormonal agents, such as adrenoglomerulotropin, octreotide, somatostatin, exenatide, teriparatide, leuprorelin and goserelin.
  • In one embodiment, the parent drug is a peptide comprising at least one heteroaromatic NH group. Such peptides include peptides comprising from 2 to about 50, from 2 to about 40, from 2 to about 20 or from 2 to about 12 amino acid residues, including at least one residue selected from tryptophan and histidine. Suitable peptides include, but are not limited to, thyrotropin releasing hormone (TRH), exenatide, daptomycin, octreotide, somatostatin, teriparatide, leuprorelin and goserelin.
  • While the heteroaromatic NH-containing parent drugs from which the prodrugs of the invention may be derived are numerous, many of the chemical structures of the prodrugs of the invention can be characterized by certain general structure types. One type includes compounds wherein the heteroaromatic group is a pyrrole group. Another type includes compounds wherein the heteroaromatic group is an imidazole group. Another type includes compounds wherein the heteroaromatic group is a 1,2,3- or 1,2,4-triazole group. Another type includes compounds wherein the heteroaromatic group is a tetrazole group. Another type includes compounds wherein the heteroaromatic group is a benzimidazole group. Another type includes compounds wherein the heteroaromatic group is an indole group. Another type includes compounds wherein the heteroaromatic group is a pyrazole group.
  • Benzimidazole-containing parent drugs which can be modified to produce prodrugs of the invention include albenazole, carbendazole, cyclobendazole, lansoprazole, liarozole, mebendazole, mizolastine, omeprazole, pantaprazole, pimobendan, rabeprazole, thiabendazole, bendazol and mibepradil. Preferred benzimidazole-containing drugs include lansoprazole, mibefradil and pimobendan.
  • Imidazole-containing parent drugs which can be modified to produce prodrugs of the invention include alosetron, ambuphylline, cimetidine, conivaptan, dexmedetomidine, ramosetron, thiamiprine, sulmazole, azathioprine, exenatide, teriparatide, thyrotropin releasing hormone (TRH), goserelin and leuprorelin. Preferred imidazole-containing drugs include conivaptan, sulmazole and azathioprine.
  • Indole-containing parent drugs which can be modified to produce prodrugs of the invention include almotriptan, atevirdine, bopindolol, bromocriptine, bucindolol, cabergoline, delavirdine, deserpidine, dolasetron, eletriptan, ergoloid mesylate, ergonovine, etodolac, frovatriptan, indoramin, lisuride, mepidolol, methylergonovine, naratriptan, oxypertine, pemetrexed, pergolide, rescinnamine, reserpine, rizatriptan, sumatriptan, tadalafil, tropisetron, adrenoglomerulotriptan, bromocriptine, ergotamine, indalpine, raubasine, reserpiline, roxindole, syrosingopine, terguride, vinblastine, vincristine, vindesine, vinorelbine, voacamine, vinflunineatevirdine, carmoxirole, rescimetol, yohimbine, zolmitriptan, octreotide, somatostatin, exenatide, teriparatide, daptomycin, leuprorelin and goserelin. Preferred indole-containing drugs include bopindolol, bucindolol, cabergoline, dolasetron, indoramin, oxypertine, pergolide, rescinnamine, reserpine, atevirdine, carmoxirole and rescimetol.
  • Pyrazole-containing parent drugs which can be modified to produce prodrugs of the invention include mepiprazole and allopurinlol.
  • Tetrazole-containing parent drugs which can be modified to produce prodrugs of the invention include candesartan, irbesartan, losartan, olmesartan, pemirolast, pranlukast, tasosartan, traxanox and valsartan.
  • Triazole-containing parent drugs which can be modified to produce prodrugs of the invention include cefatrizine and alizapride.
  • Particularly preferred parent drugs which can be modified according to the invention include bopindolol, bucindolol, cabergoline, candesartan, cefatrizine, conivaptan, indoramin, irbesartan, lansoprazole, mibefradil, olmesartan, oxypertine, pemirolast, pergolide, pimobendan, rescinnamine, reserpine, valsartan, sulmazole, azathioprine, atevirdine, carmoxirole and rescimetol.
  • In one embodiment, the parent drug moieties (APIs) are selected from Table 13. In one embodiment, the prodrug is a compound of Formula II wherein API-1 and API-2 are selected from Table 13. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 13
    Figure US20160024011A1-20160128-C00446
    Figure US20160024011A1-20160128-C00447
    Figure US20160024011A1-20160128-C00448
    Figure US20160024011A1-20160128-C00449
    Figure US20160024011A1-20160128-C00450
    Figure US20160024011A1-20160128-C00451
    Figure US20160024011A1-20160128-C00452
    Figure US20160024011A1-20160128-C00453
    Figure US20160024011A1-20160128-C00454
    Figure US20160024011A1-20160128-C00455
    Figure US20160024011A1-20160128-C00456
    Figure US20160024011A1-20160128-C00457
    Figure US20160024011A1-20160128-C00458
    Figure US20160024011A1-20160128-C00459
    Figure US20160024011A1-20160128-C00460
    Figure US20160024011A1-20160128-C00461
    Figure US20160024011A1-20160128-C00462
    Figure US20160024011A1-20160128-C00463
    Figure US20160024011A1-20160128-C00464
    Figure US20160024011A1-20160128-C00465
    Figure US20160024011A1-20160128-C00466
    Figure US20160024011A1-20160128-C00467
    Figure US20160024011A1-20160128-C00468
    Figure US20160024011A1-20160128-C00469
    Figure US20160024011A1-20160128-C00470
  • In another aspect of the invention a general method to synthesize prodrugs that can be linked to multiple drug molecules is provided (Scheme 1).
  • Figure US20160024011A1-20160128-C00471
  • wherein each LG-1 and LG-2 is independently a leaving group, preferably a chloride, bromide or iodide.
  • In another aspect of the invention a general method to synthesize prodrugs that can be linked to two parent drug molecules through alkyl group is provided (Scheme 2). The same methodology can be used to synthesize prodrugs with branched and substituted alkyl groups.
  • Figure US20160024011A1-20160128-C00472
  • wherein n is an integer between about 1 and about 50, preferably between about 4 and about 26.
  • In one embodiment, the dicarboxylic acid from Scheme 2 is selected from oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, undecanedioic acid, dodecanedioic acid, ortho-, para- or meta-phthalic acid, maleic acid, fumaric acid, glutaconic acid, traumatic acid or muconic acid. In one embodiment, the dicarboxylic acid is reacted with one mole equivalent or less of thionyl chloride to give a mixture of mono and disubstituted acid chloride. In another embodiment, the dicarobxylic acid is reacted with two or more mole equivalents of thionyl chloride. The acid chlorides can be converted to chloromethyl esters by reacting with trioxane or paraformaldehyde using zirconium tetrachloride as the Lewis acid. (Mudryk, B. et. al., Tetrahedron Letters 43(36), 2002, 6317-6318). The chloromethyl esters can be reacted with reactive APIs, such as amine containing pharmacophores to give the final conjugates. Methods for attaching biologically active agents containing amine groups through labile groups are disclosed in U.S. application Ser. No. 12/823,102. The methods described therein can be adapted to convert dicarboxylic acid containing carrier groups herein.
  • In another aspect of the invention a general method to synthesize prodrugs of aripiprazole that can be linked to two aripiprazole molecules through alkyl group is provided (Scheme 3). The invention further provides a prodrug of aripiprazole selected from Table 14.
  • Figure US20160024011A1-20160128-C00473
  • TABLE A
    Compound No. Structure
     1
    Figure US20160024011A1-20160128-C00474
     2
    Figure US20160024011A1-20160128-C00475
     3
    Figure US20160024011A1-20160128-C00476
     4
    Figure US20160024011A1-20160128-C00477
     5
    Figure US20160024011A1-20160128-C00478
     6
    Figure US20160024011A1-20160128-C00479
     7
    Figure US20160024011A1-20160128-C00480
     8
    Figure US20160024011A1-20160128-C00481
     9
    Figure US20160024011A1-20160128-C00482
    10
    Figure US20160024011A1-20160128-C00483
    11
    Figure US20160024011A1-20160128-C00484
    12
    Figure US20160024011A1-20160128-C00485
  • In one embodiment, the compounds of Formula I, IA or IB are less soluble, and are preferably at least an order of magnitude less soluble, as compared to the parent drug from which they were derived. In one embodiment, the prodrugs of Formula I, IA or IB have an aqueous solubility of less than about 0.5 mg/ml, preferably less than about 0.1 mg/mL, preferably less than about 0.01 mg/mL, preferably less than about 0.001 mg/mL, preferably less than about 0.0001 mg/mL and even more preferably less than about 0.00001 mg/ml when solubility is measured in a phosphate buffer (pH 7.4) at room temperature.
  • In a preferred embodiment, a compound of the invention provides sustained delivery of the parent drug over hours, days, weeks or months when administered, for example, orally or parenterally, to a subject. For example, the compounds can provide sustained delivery of the parent drug for at least 8, 12, 24, 36 or 48 hours or at least 4, 7, 15, 30, 60, 75 or 90 days or longer. Without being bound by a theory, it is believed that the compounds of the invention form an insoluble depot upon parenteral administration, for example subcutaneous, intramuscular or intraperitoneal injection. In one embodiment a prodrug of the invention may further comprise a sustained release delivery system for providing additional protection of the prodrug from enzymatic or chemical degradation.
  • In another embodiment, the invention provides a method for sustained delivery of a parent lactam, amide, imide, sulfonamide, carbamate, urea, benzamide, or acylaniline containing drug to a subject in need thereof. Each of these groups comprises an amidic N—H group. The method comprises administering to the subject an effective amount of a prodrug formed by substituting on the NH group a labile, hydrophobic aldehyde-linked prodrug moiety wherein the prodrug has reduced solubility under physiological conditions compared to the parent drug and provides for longer sustained therapeutic levels of the parent drug following administration than observed levels following administration of the parent drug. In a preferred embodiment, the amidic N—H group has a pKa of about 5 to about 22, preferably about 5 to about 21, and preferably about 5 to about 20.
    • Prodrugs of Secondary Amine Drugs
  • The invention further relates to prodrugs of secondary amine containing drugs of Formula LI:
  • Figure US20160024011A1-20160128-C00486
  • In some embodiments, the invention relates to a prodrug conjugate having the formula:
  • Figure US20160024011A1-20160128-C00487
  • wherein A1 and B1 together with the nitrogen they are attached to form a first biologically active molecule; and,
    A2 and B2 together with the nitrogen they are attached to form a second biologically active molecule.
  • In some embodiments, the invention relates to a prodrug of a secondary amine containing parent drug having the Formula LI-A:
  • Figure US20160024011A1-20160128-C00488
  • wherein n is an integer between about 1 and about 50;
    • X1 is S or O;
  • X2 is selected from direct bond, O, S or NR20;
    each R10 and R11 is independently selected from absent, hydrogen, halogen, —OR20, —SR20, —NR20R21, —C(O)R20, —C(O)OR20, —C(O)NR20R21, —N(R20)C(O)R21, —CF3, —CN, —NO2, —N3, acyl, optionally substituted alkoxy, optionally substituted alkylamino, optionally substituted dialkylamino, optionally substituted alkylthio, optionally substituted alkylsulfonyl, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; wherein each R20 and R21 is selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl;
    alternatively two R10 and R11 together with the atoms to which they are attached may form an optionally substituted 3, 4, 5, 6 or 7 membered carbocyclic or heterocyclyl ring.
  • In a preferred embodiment, n is selected from 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30.
  • The secondary amine-containing parent drugs (designated in Formula LI as API-1 and API-2) can be any secondary amine-containing parent drug that induces a desired local or systemic effect. Such parent drugs include broad classes of compounds. Several examples include: respiratory drugs, including antiasthmatic agents; analgesic agents; antidepressants; antianginal agents; antiarrhythmic agents; antihypertensive agents; antidiabetic agents; antihistamines; anti-infective agents such as antibiotics; antiinflammatory agents; antiparkinsonism drugs; antipsychotics; antipyretic agents; antiulcer agents; attention deficit hyperactivity disorder (ADHD) drugs; central nervous system stimulants; cough and cold preparations, including decongestants; and psychostimulants.
  • Examples of secondary-amine containing parent drugs from which prodrugs of the invention may be derived include: alprenolol, acebutolol, amidephrine, amineptine, amosulalol, amoxapine, amphetaminil, atenolol, atomoxetine, balofloxacin, bamethan, befunolol, benazepril, benfluorex, benzoctamine, betahistine, betaxolol, bevantolol, bifemelane, bisoprolol, brinzolamide, bufeniode, butethamine, camylofine, carazolol, carticaine, carvedilol, cephaeline, ciprofloxacin, clozapine, clobenzorex, clorprenaline, cyclopentamine, delapril, demexiptiline, denopamine, desipramine, desloratadine (clarinex), diclofenac, dimetofrine, dioxadrol, dobutamine, dopexamine, doripenem, dorzolamide, droprenilamine, duloxetine, eltoprazine, enalapril, enoxacin, epinephrine, ertapenem, esaprazole, esmolol, etoxadrol, fasudil, fendiline, fenethylline, fenfluramine, fenoldopam, fenoterol, fenproporex, flecainide, fluoxetine, formoterol, frovatriptan, gaboxadol, garenoxacin, gatifloxacin, grepafloxacin, hexoprenaline, imidapril, indalpine, indecainide, indeloxazine hydrochloride, isoxsuprine, ispronicline, labetalol, landiolol, lapatinib, levophacetoperane, lisinopril, lomefloxacin, lotrafiban, maprotiline, mecamylamine, mefloquine, mepindolol, meropenem, metapramine, metaproterenol, methoxyphenamine, dtmp (dextrorotary methylphenidate), methylphenidate, metipranolol, metoprolol, mitoxantrone, mivazerol, moexipril, moprolol, moxifloxacin, nebivolol, nifenalol, nipradilol, norfloxacin, nortriptyline, nylidrin, olanzapine, oxamniquine, oxprenolol, oxyfedrine, paroxetine, perhexiline, phenmetrazine, phenylephrine, phenylpropylmethylamine, pholedrine, picilorex, pimefylline, pindolol, pipemidic acid, piridocaine, practolol, pradofloxacin, pramipexole, pramiverin, prenalterol, prenylamine, prilocaine, procaterol, pronethalol, propafenone, propranolol, propylhexedrine, protokylol, protriptyline, pseudoephedrine, reboxetine, rasagiline, (r)-rasagiline, repinotan, reproterol, rimiterol, ritodrine, safinamide, salbutamol/albuterol, salmeterol, sarizotan, sertraline, silodosin, sotalol, soterenol, sparfloxacin, spirapril, sulfinalol, synephrine, tamsulosin, tebanicline, tianeptine, tirofiban, tretoquinol, trimetazidine, troxipide, varenicline (champix), vildagliptin, viloxazine, viquidil and xamoterol.
  • Preferred secondary amine-containing parent drugs from which prodrugs of the invention are derived include atenolol, atomoxetine, clozapine, desipramine, desloratadine (clarinex), diclofenac, doripenem, duloxetine, enalapril, ertapenem, fluoxetine, metoprolol, mecamylamine, meropenem, methylphenidate, dtmp (dextrorotary methylphenidate), olanzapine, paroxetine, pramipexole, rasagiline, ®-RASAGILINE, salbutamol/albuterol, tamsulosin, varenicline (hantix), and vildagliptin. In a more preferred embodiment, the secondary amine-containing parent drug is selected from clozapine, duloxetine, mecamylamine, pramipexole, rasagiline, ®-RASAGILINE, and olanzapine.
  • In one embodiment, the parent drug moieties (APIs) are selected from Table 14. In one embodiment, the prodrug is a compound of Formula LI or LI-A wherein API-1 and API-2 are selected from Table 14. In one embodiment both API-1 and API-2 represent the same parent drug.
  • TABLE 14
    Figure US20160024011A1-20160128-C00489
    Figure US20160024011A1-20160128-C00490
    Figure US20160024011A1-20160128-C00491
    Figure US20160024011A1-20160128-C00492
    Figure US20160024011A1-20160128-C00493
    Figure US20160024011A1-20160128-C00494
    Figure US20160024011A1-20160128-C00495
    Figure US20160024011A1-20160128-C00496
    Figure US20160024011A1-20160128-C00497
    Figure US20160024011A1-20160128-C00498
    Figure US20160024011A1-20160128-C00499
    Figure US20160024011A1-20160128-C00500
    Figure US20160024011A1-20160128-C00501
    Figure US20160024011A1-20160128-C00502
    Figure US20160024011A1-20160128-C00503
    Figure US20160024011A1-20160128-C00504
    Figure US20160024011A1-20160128-C00505
    Figure US20160024011A1-20160128-C00506
    Figure US20160024011A1-20160128-C00507
    Figure US20160024011A1-20160128-C00508
    Figure US20160024011A1-20160128-C00509
    Figure US20160024011A1-20160128-C00510
    Figure US20160024011A1-20160128-C00511
    Figure US20160024011A1-20160128-C00512
    Figure US20160024011A1-20160128-C00513
    Figure US20160024011A1-20160128-C00514
  • In a more preferred embodiment, the invention relates to a prodrug of olanzapine represented by formula:
  • Figure US20160024011A1-20160128-C00515
  • In a more preferred embodiment, the invention relates to a prodrug of olanzapine represented by formula:
  • Figure US20160024011A1-20160128-C00516
  • In a preferred embodiment, the invention relates to a prodrug of olanzapine represented by formula:
  • Figure US20160024011A1-20160128-C00517
  • In a more preferred embodiment, the invention relates to a prodrug of olanzapine represented by formula:
  • Figure US20160024011A1-20160128-C00518
  • In a more preferred embodiment, the invention relates to a prodrug of olanzapine represented by formula:
  • Figure US20160024011A1-20160128-C00519
  • In a more preferred embodiment, the invention relates to a prodrug of olanzapine represented by formula:
  • Figure US20160024011A1-20160128-C00520
  • In a more preferred embodiment, the invention relates to a prodrug of olanzapine represented by formula:
  • Figure US20160024011A1-20160128-C00521
  • In a more preferred embodiment, the invention relates to a prodrug of olanzapine represented by formula:
  • Figure US20160024011A1-20160128-C00522
  • In a more preferred embodiment, the invention relates to a prodrug of olanzapine represented by formula:
  • Figure US20160024011A1-20160128-C00523
  • In a preferred embodiment, the invention relates to a prodrug of olanzapine represented by formula:
  • Figure US20160024011A1-20160128-C00524
    • Synthesis of Compounds
  • Generally, the compounds of the invention can be synthesized by the method set forth in Schemes 3A and 3B where derivatization of olanzapine is illustrated.
  • Figure US20160024011A1-20160128-C00525
  • Figure US20160024011A1-20160128-C00526
  • Schemes 3A and 3B illustrate the synthesis of a compound of Formula LI by condensation of the parent drug, olanzapine, with chloromethyl chloroformate, followed by condensation with a carboxylic acid.
    • DEFINITIONS
  • Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.
  • The terms “API”, “biologically active moiety”, “drug moiety” and “parent drug moiety” are used interchangeably to refer to the structure of a parent drug molecule which is present in a prodrug conjugate of the invention. As will be understood by one of skill in the art, in certain embodiments, linking the drug molecule to a carrier moiety proceeds via substitution at an oxygen or nitrogen atom of the parent drug molecule with loss of a hydrogen atom. In these embodiments, the parent drug moiety is the radical resulting from removal of the O—H or N—H hydrogen atom from the parent drug molecule. In certain embodiments, the carrier moiety is linked to the parent drug molecule without any loss of atoms from the parent drug molecule. In these embodiments, the parent drug moiety includes the entire structure of the parent drug compound. For example, in case of a tertiary amine parent drug that is converted to a quaternary prodrug conjugate a loss of hydrogen from the parent drug doesn't occur.
  • The term “aliphatic group” or “aliphatic” refers to a non-aromatic moiety that may be saturated (e.g., single bond) or contain one or more units of unsaturation, e.g., double and/or triple bonds. An aliphatic group may be straight chained, branched or cyclic, contain carbon, hydrogen or, optionally, one or more heteroatoms and may be substituted or unsubstituted. In addition to aliphatic hydrocarbon groups, aliphatic groups include, for example, polyalkoxyalkyls, such as polyalkylene glycols, polyamines, and polyimines, for example. Such aliphatic groups may be further substituted. It is understood that aliphatic groups may include alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, and substituted or unsubstituted cycloalkyl groups as described herein.
  • The term “acyl” refers to a carbonyl substituted with hydrogen, alkyl, partially saturated or fully saturated cycloalkyl, partially saturated or fully saturated heterocycle, aryl, or heteroaryl. For example, acyl includes groups such as (C1-C6) alkanoyl (e.g., formyl, acetyl, propionyl, butyryl, valeryl, caproyl, t-butylacetyl, etc.), (C3-C6)cycloalkylcarbonyl (e.g., cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, etc.), heterocyclic carbonyl (e.g., pyrrolidinylcarbonyl, pyrrolid-2-one-5-carbonyl, piperidinylcarbonyl, piperazinylcarbonyl, tetrahydrofuranylcarbonyl, etc.), aroyl (e.g., benzoyl) and heteroaroyl (e.g., thiophenyl-2-carbonyl, thiophenyl-3-carbonyl, furanyl-2-carbonyl, furanyl-3-carbonyl, 1H-pyrroyl-2-carbonyl, 1H-pyrroyl-3-carbonyl, benzo[b]thiophenyl-2-carbonyl, etc.). In addition, the alkyl, cycloalkyl, heterocycle, aryl and heteroaryl portion of the acyl group may be any one of the groups described in the respective definitions. When indicated as being “optionally substituted”, the acyl group may be unsubstituted or optionally substituted with one or more substituents (typically, one to three substituents) independently selected from the group of substituents listed below in the definition for “substituted” or the alkyl, cycloalkyl, heterocycle, aryl and heteroaryl portion of the acyl group may be substituted as described above in the preferred and more preferred list of substituents, respectively.
  • The term “alkyl” is intended to include both branched and straight chain, substituted or unsubstituted saturated aliphatic hydrocarbon radicals/groups having the specified number of carbons. Preferred alkyl groups comprise about 1 to about 24 carbon atoms (“C1-C24”) preferably about 7 to about 24 carbon atoms (“C7-C24”), preferably about 8 to about 24 carbon atoms (“C8-C24”), preferably about 9 to about 24 carbon atoms (“C9-C24”). Other preferred alkyl groups comprise at about 1 to about 8 carbon atoms (“C1-C8”) such as about 1 to about 6 carbon atoms (“C1-C6”), or such as about 1 to about 3 carbon atoms (“C1-C3”). Examples of C1-C6 alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, neopentyl and n-hexyl radicals.
  • The term “alkenyl” refers to linear or branched radicals having at least one carbon-carbon double bond. Such radicals preferably contain from about two to about twenty-four carbon atoms (“C2-C24”) preferably about 7 to about 24 carbon atoms (“C7-C24”), preferably about 8 to about 24 carbon atoms (“C8-C24”), and preferably about 9 to about 24 carbon atoms (“C9-C24”). Other preferred alkenyl radicals are “lower alkenyl” radicals having two to about ten carbon atoms (“C2-C10”) such as ethenyl, allyl, propenyl, butenyl and 4-methylbutenyl. Preferred lower alkenyl radicals include 2 to about 6 carbon atoms (“C2-C6”). The terms “alkenyl”, and “lower alkenyl”, embrace radicals having “cis” and “trans” orientations, or alternatively, “E” and “Z” orientations.
  • The term “alkynyl” refers to linear or branched radicals having at least one carbon-carbon triple bond. Such radicals preferably contain from about two to about twenty-four carbon atoms (“C2-C24”) preferably about 7 to about 24 carbon atoms (“C7-C24”), preferably about 8 to about 24 carbon atoms (“C8-C24”), and preferably about 9 to about 24 carbon atoms (“C9-C24”). Other preferred alkynyl radicals are “lower alkynyl” radicals having two to about ten carbon atoms such as propargyl, 1-propynyl, 2-propynyl, 1-butyne, 2-butynyl and 1-pentynyl. Preferred lower alkynyl radicals include 2 to about 6 carbon atoms (“C2-C6”).
  • The term “cycloalkyl” refers to saturated carbocyclic radicals having three to about twelve carbon atoms (“C3-C12”). The term “cycloalkyl” embraces saturated carbocyclic radicals having three to about twelve carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • The term “cycloalkenyl” refers to partially unsaturated carbocyclic radicals having three to twelve carbon atoms. Cycloalkenyl radicals that are partially unsaturated carbocyclic radicals that contain two double bonds (that may or may not be conjugated) can be called “cycloalkyldienyl”. More preferred cycloalkenyl radicals are “lower cycloalkenyl” radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl and cyclohexenyl.
  • The term “alkylene,” as used herein, refers to a divalent group derived from a straight chain or branched saturated hydrocarbon chain having the specified number of carbons atoms. Examples of alkylene groups include, but are not limited to, ethylene, propylene, butylene, 3-methyl-pentylene, and 5-ethyl-hexylene.
  • The term “alkenylene,” as used herein, denotes a divalent group derived from a straight chain or branched hydrocarbon moiety containing the specified number of carbon atoms having at least one carbon-carbon double bond. Alkenylene groups include, but are not limited to, for example, ethenylene, 2-propenylene, 2-butenylene, 1-methyl-2-buten-1-ylene, and the like.
  • The term “alkynylene,” as used herein, denotes a divalent group derived from a straight chain or branched hydrocarbon moiety containing the specified number of carbon atoms having at least one carbon-carbon triple bond. Representative alkynylene groups include, but are not limited to, for example, propynylene, 1-butynylene, 2-methyl-3-hexynylene, and the like.
  • The term “alkoxy” refers to linear or branched oxy-containing radicals each having alkyl portions of one to about twenty-four carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkoxy radicals are “lower alkoxy” radicals having one to about ten carbon atoms and more preferably having one to about eight carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy.
  • The term “alkoxyalkyl” refers to alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals.
  • The term “aryl”, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term “aryl” embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl.
  • The terms “heterocyclyl”, “heterocycle” “heterocyclic” or “heterocyclo” refer to saturated, partially unsaturated and unsaturated heteroatom-containing ring-shaped radicals, which can also be called “heterocyclyl”, “heterocycloalkenyl” and “heteroaryl” correspondingly, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclyl radicals include saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms (e.g., pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g., morpholinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partially unsaturated heterocyclyl radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole. Heterocyclyl radicals may include a pentavalent nitrogen, such as in tetrazolium and pyridinium radicals. The term “heterocycle” also embraces radicals where heterocyclyl radicals are fused with aryl or cycloalkyl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like.
  • The term “heteroaryl” refers to unsaturated aromatic heterocyclyl radicals. Examples of heteroaryl radicals include unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.; unsaturated condensed heterocyclyl group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl, etc.), etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing a sulfur atom, for example, thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g., benzoxazolyl, benzoxadiazolyl, etc.); unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., benzothiazolyl, benzothiadiazolyl, etc.) and the like.
  • The term “heterocycloalkyl” refers to heterocyclo-substituted alkyl radicals. More preferred heterocycloalkyl radicals are “lower heterocycloalkyl” radicals having one to six carbon atoms in the heterocyclo radical.
  • The term “alkylthio” refers to radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms attached to a divalent sulfur atom. Preferred alkylthio radicals have alkyl radicals of one to about twenty-four carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkylthio radicals have alkyl radicals which are “lower alkylthio” radicals having one to about ten carbon atoms. Most preferred are alkylthio radicals having lower alkyl radicals of one to about eight carbon atoms. Examples of such lower alkylthio radicals include methylthio, ethylthio, propylthio, butylthio and hexylthio.
  • The terms “aralkyl” or “arylalkyl” refer to aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl.
  • The term “aryloxy” refers to aryl radicals attached through an oxygen atom to other radicals.
  • The terms “aralkoxy” or “arylalkoxy” refer to aralkyl radicals attached through an oxygen atom to other radicals.
  • The term “aminoalkyl” refers to alkyl radicals substituted with amino radicals. Preferred aminoalkyl radicals have alkyl radicals having about one to about twenty-four carbon atoms or, preferably, one to about twelve carbon atoms. More preferred aminoalkyl radicals are “lower aminoalkyl” that have alkyl radicals having one to about ten carbon atoms. Most preferred are aminoalkyl radicals having lower alkyl radicals having one to eight carbon atoms. Examples of such radicals include aminomethyl, aminoethyl, and the like.
  • The term “alkylamino” denotes amino groups which are substituted with one or two alkyl radicals. Preferred alkylamino radicals have alkyl radicals having about one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkylamino radicals are “lower alkylamino” that have alkyl radicals having one to about ten carbon atoms. Most preferred are alkylamino radicals having lower alkyl radicals having one to about eight carbon atoms. Suitable lower alkylamino may be monosubstituted N-alkylamino or disubstituted N,N-alkylamino, such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino or the like.
  • The term “substituted” refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl, heteroaryl, heterocyclic, and aliphatic. It is understood that the substituent may be further substituted.
  • For simplicity, chemical moieties that are defined and referred to throughout can be univalent chemical moieties (e.g., alkyl, aryl, etc.) or multivalent moieties under the appropriate structural circumstances clear to those skilled in the art. For example, an “alkyl” moiety can be referred to a monovalent radical (e.g. CH3—CH2—), or in other instances, a bivalent linking moiety can be “alkyl,” in which case those skilled in the art will understand the alkyl to be a divalent radical (e.g., —CH2—CH2—), which is equivalent to the term “alkylene.” Similarly, in circumstances in which divalent moieties are required and are stated as being “alkoxy”, “alkylamino”, “aryloxy”, “alkylthio”, “aryl”, “heteroaryl”, “heterocyclic”, “alkyl” “alkenyl”, “alkynyl”, “aliphatic”, or “cycloalkyl”, those skilled in the art will understand that the terms alkoxy”, “alkylamino”, “aryloxy”, “alkylthio”, “aryl”, “heteroaryl”, “heterocyclic”, “alkyl”, “alkenyl”, “alkynyl”, “aliphatic”, or “cycloalkyl” refer to the corresponding divalent moiety.
  • The terms “halogen” or “halo” as used herein, refers to an atom selected from fluorine, chlorine, bromine and iodine.
  • The terms “compound” “drug”, and “prodrug” as used herein all include pharmaceutically acceptable salts, co-crystals, solvates, hydrates, polymorphs, enantiomers, diastereoisomers, racemates and the like of the compounds, drugs and prodrugs having the formulas as set forth herein.
  • Substituents indicated as attached through variable points of attachments can be attached to any available position on the ring structure.
  • As used herein, the term “effective amount of the subject compounds,” with respect to the subject method of treatment, refers to an amount of the subject compound which, when delivered as part of desired dose regimen, brings about management of the disease or disorder to clinically acceptable standards.
  • “Treatment” or “treating” refers to an approach for obtaining beneficial or desired clinical results in a patient. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, one or more of the following: alleviation of symptoms, diminishment of extent of a disease, stabilization (i.e., not worsening) of a state of disease, preventing spread (i.e., metastasis) of disease, preventing occurrence or recurrence of disease, delay or slowing of disease progression, amelioration of the disease state, and remission (whether partial or total).
  • The term “labile” as used herein refers to the capacity of the prodrug of the invention to undergo enzymatic and/or chemical cleavage in vivo thereby forming the parent drug. As used herein the term “prodrug” means a compounds as disclosed herein which is a labile derivative compound of a parent drug which when administered to a patient in vivo becomes cleaved by chemical and/or enzymatic hydrolysis thereby forming the parent drug such that a sufficient amount of the compound intended to be delivered to the patient is available for its intended therapeutic use in a sustained release manner.
  • The term “dendrimer” refers to a class of highly branched, often spherical, macromolecular polymers that exhibit greater monodispersity (i.e., a smaller range of molecular weights, sizes, and shapes) than linear polymers of similar size. These three-dimensional oligomeric structures are prepared by reiterative reaction sequences starting from a core molecule (such as diaminobutane or ethylenediamine) that has multiple reactive groups. When monomer units, also having multiple reactive groups, are reacted with the core, the number of reactive groups comprising the outer bounds of the dendrimer increases. Successive layers of monomer molecules may be added to the surface of the dendrimer, with the number of branches and reactive groups on the surface increasing geometrically each time a layer is added. The number of layers of monomer molecules in a dendrimer may be referred to as the “generation” of the dendrimer. The total number of reactive functional groups on a dendrimer's outer surface ultimately depends on the number of reactive groups possessed by the core, the number of reactive groups possessed by the monomers that are used to grow the dendrimer, and the generation of the dendrimer.
    • Pharmaceutical Compositions
  • The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers or excipients.
  • As used herein, the term “pharmaceutically acceptable carrier or excipient” means a non-toxic, inert solid, semi-solid, gel or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; cyclodextrins such as alpha-(α), beta-(β) and gamma-(γ) cyclodextrins; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
  • The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. In a preferred embodiment, administration is parenteral administration by injection.
  • The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable suspension or emulsion, such as INTRALIPID®, LIPOSYN® or OMEGAVEN®, or solution, in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. INTRALIPID® is an intravenous fat emulsion containing 10-30% soybean oil, 1-10% egg yolk phospholipids, 1-10% glycerin and water. LIPOSYN® is also an intravenous fat emulsion containing 2-15% safflower oil, 2-15% soybean oil, 0.5-5% egg phosphatides 1-10% glycerin and water. OMEGAVEN® is an emulsion for infusion containing about 5-25% fish oil, 0.5-10% egg phosphatides, 1-10% glycerin and water. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, USP and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
  • The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • Additional sustained release in accordance with the invention may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.
  • In one preferred embodiment, the formulation provides a sustained release delivery system that is capable of minimizing the exposure of the prodrug to water. This can be accomplished by formulating the prodrug with a sustained release delivery system that is a polymeric matrix capable of minimizing the diffusion of water into the matrix. Suitable polymers comprising the matrix include polylactide (PLA) polymers and the lactide/glycolide (PLGA) co-polymers.
  • Alternatively, the sustained release delivery system may comprise poly-anionic molecules or resins that are suitable for injection or oral delivery. Suitable polyanionic molecules include cyclodextrins and polysulfonates formulated to form a poorly soluble mass that minimizes exposure of the prodrug to water and from which the prodrug slowly leaves.
  • Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
  • The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • For pulmonary delivery, a therapeutic composition of the invention is formulated and administered to the patient in solid or liquid particulate form by direct administration e.g., inhalation into the respiratory system. Solid or liquid particulate forms of the active compound prepared for practicing the present invention include particles of respirable size: that is, particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and alveoli of the lungs. Delivery of aerosolized therapeutics, particularly aerosolized antibiotics, is known in the art (see, for example U.S. Pat. No. 5,767,068 to VanDevanter et al., U.S. Pat. No. 5,508,269 to Smith et al., and WO 98/43650 by Montgomery, all of which are incorporated herein by reference). A discussion of pulmonary delivery of antibiotics is also found in U.S. Pat. No. 6,014,969, incorporated herein by reference.
  • By a “therapeutically effective amount” of a prodrug compound of the invention is meant an amount of the compound which confers a therapeutic effect on the treated subject, at a reasonable benefit/risk ratio applicable to any medical treatment. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
  • In accordance with the invention, the therapeutically effective amount of a prodrug of the invention is typically based on the target therapeutic amount of the parent drug. Information regarding dosing and frequency of dosing is readily available for many parent drugs from which the prodrugs of the invention are derived and the target therapeutic amount can be calculated for each prodrug of the invention. In accordance with the invention, the same dose of a prodrug of the invention provides a longer duration of therapeutic effect as compared to the parent drug. Thus if a single dose of the parent drug provides 12 hours of therapeutic effectiveness, a prodrug of that same parent drug in accordance with the invention that provides therapeutic effectiveness for greater than 12 hours will be considered to achieve a “sustained release”.
  • The precise dose of a prodrug of the invention depends upon several factors including the nature and dose of the parent drug and the chemical characteristics of the prodrug moiety linked to the parent drug. Ultimately, the effective dose and dose frequency of a prodrug of the invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level and dose frequency for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or contemporaneously with the specific compound employed; and like factors well known in the medical arts.
    • Examples STEP 1: Synthesis of 7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-1-(hydroxymethyl)-3,4-dihydroquinolin-2(1H)-one
  • Figure US20160024011A1-20160128-C00527
    • Procedure:
  • A mixture of Aripiprazole (5.2 g, 0.012 mol), triethylamine (0.25 mL, 0.0018 mol), 37% aqueous formaldehyde solution (18.5 mL) and dimethylformamide (50 mL) was heated at 80° C. for 48 hours. After 48 hours the reaction mixture was cooled to ambient temperature, diluted with ethyl acetate (200 mL) and washed with water (2×200 mL) and brine (2×200 mL). The organic phase was dried with sodium sulphate, filtered and concentrated in vacuo to give hemi-aminal as a white solid [5.6 g, containing 43% Aripiprazole and 56% hemi-aminal (as per LCMS analysis)].
    • Synthesis of Bis((7-(4-(4-(2,3-dichlorophenyl) piperazin-1-yl) butoxy)-2oxo-3,4-dihydroquinolin-1(2H)-yl)methyl) decanedioate
  • Figure US20160024011A1-20160128-C00528
    • Procedure:
  • A solution of Step-1 reaction mixture (1.0 g, 0.0021 mol) in dichloromethane (20 mL) was stirred at 25° C. under nitrogen atmosphere. Triethylamine (1.45 mL, 0.0105 mol) was added drop wise to the above solution at 25° C. and the resulting reaction mixture was allowed to stir at the same temperature for next 10 minutes. After 10 minutes a solution of sebacoyl chloride in dichloromethane (0.223 mL, 0.00105 mol sebacoyl chloride in 2.2 mL dichloromethane) was added drop wise to the above reaction mixture at 25° C. The resulting clear reaction mixture was warmed to 45° C. whereby it was allowed to stir for next 2 hours. The reaction mixture was partitioned between dichloromethane (100 mL) and water (200 mL) and the aqueous layer was extracted with dichloromethane (2×100 mL). The combined organic fractions were washed with brine (100 mL), dried over sodium sulphate, filtered and concentrated in vacuo. The product was purified by flash chromatography using dichloromethane: methanol as mobile phase and the desired product eluted at around 1.5% methanol in dichloromethane to provide Compound-6 [0.3 g, 22% yield].
  • 1H NMR (DMSO, 400 MHz) δ 1.171 (s, 8H), 1.44-1.49 (m, 4H), 1.56-1.61 (m, 4H), 1.69-1.76 (m, 4H), 2.29 (t, 4H), 2.37 (t, 4H), 2.57 (t, 4H), 2.80 (t, 4H), 2.95 (broad s, 8H), 3.35 (broad s, 8H), 3.97 (t, 4H), 5.86 (broad s, 4H), 6.63-6.65 (m, 4H), 7.09-7.14 (m, 4H), 7.27-7.31 (m, 4H); m/z (M+H) 1123.
    • Synthesis of Compound-7: Bis((7-(4-(4-(2,3-dichlorophenyl) piperazin-1-yl) butoxy)-2oxo-3,4-dihydroquinolin-1(2H)-yl)methyl) dodecanedioate
  • Figure US20160024011A1-20160128-C00529
    • Procedure:
  • A solution of Step-1 (1.0 g, 0.0021 mol) in dichloromethane (20 mL) was stirred at 25° C. under nitrogen atmosphere. Triethylamine (1.45 mL, 0.0105 mol) was added drop wise to the above solution at 25° C. and the resulting reaction mixture was allowed to stir at the same temperature for next 10 minutes. After 10 minutes a solution of dodecandioyl dichloride in dichloromethane (0.280 g, 0.00105 mol dodecandioyl dichloride in 2.5 mL dichloromethane) was added drop wise to the above reaction mixture at 25° C. The resulting clear reaction mixture was warmed to 45° C. whereby it was allowed to stir for next 2 hours. The reaction mixture was partitioned between dichloromethane (100 mL) and water (200 mL) and the aqueous layer was extracted with dichloromethane (2×100 mL). The combined organic were washed with brine (100 mL), dried over sodium sulphate, filtered and concentrated in vacuo. The product was purified by flash chromatography using dichloromethane: methanol as mobile phase and the desired product eluted at around 1.5% methanol in dichloromethane. Distillation of the product fractions provided Compound-7 [0.160 g, 11% yield].
  • 1H NMR (DMSO, 400 MHz) δ 1.16-1.18 (s, 12H), 1.47-1.50 (m, 4H), 1.57-1.62 (m, 4H), 1.71-1.75 (m, 4H), 2.28-2.32 (t, 4H), 2.38 (t, 4H), 2.57 (t, 4H), 2.80 (t, 4H), 2.95 (broad s, 8H), 3.34 (broad s, 8H), 3.97 (t, 4H), 5.86 (broad s, 4H), 6.63-6.65 (m, 4H), 7.10-7.15 (m, 4H), 7.28-7.31 (m, 4H); m/z (M+H) 1149.7.
    • Synthesis of Compound-8 Synthesis of Tetradecandioyl Dichloride
  • Oxalyl chloride (1.35 mL, 0.015 mol) was added drop wise to a solution of Tetradecandioyl dichloride (1.0 g, 0.0039 mol) in dichloromethane at 25° C. After the addition was completed, the reaction mixture was stirred at same temperature for 2 hours, the reaction mixture was partitioned between dichloromethane (100 mL) and water (200 mL), the aqueous layer was extracted with dichloromethane (2×100 mL). The combined organic extracts were washed with brine (200 mL), dried over sodium sulphate filtered and concentrated in vacuo to provide the desired product (0.9 g, 90% yield) as a colorless liquid which was used directly for the next step without further purification.
    • Synthesis of Bis((7-(4-(4-(2,3-dichlorophenyl) piperazin-1-yl) butoxy)-2oxo-3,4-dihydroquinolin-1(2H)-yl)methyl)tetradecanedioate
  • Figure US20160024011A1-20160128-C00530
  • A solution of Step-1 (1.0 g, 0.0021 mol) in dichloromethane (20 mL) was stirred at 25° C. under nitrogen atmosphere. Triethylamine (1.45 mL g, 0.0105 mol) was added drop wise to the above solution at 25° C. and the resulting reaction mixture was allowed to stir at the same temperature for next 10 minutes. After 10 minutes a solution of tetradecandioyl dichloride in dichloromethane (0.308 g, 0.00105 mol tetradecandioyl dichloride in 3.0 mL dichloromethane) was added drop wise to the above reaction mixture at 25° C. The resulting clear reaction mixture was warmed to 45° C. whereby it was allowed to stir for next 2 hours. The reaction mixture was partitioned between dichloromethane (100 mL) and water (200 mL) and the aqueous layer was extracted with dichloromethane (2×100 mL). The combined organic were washed with brine (200 mL), dried over sodium sulphate, filtered and concentrated in vacuo. The product was purified by flash chromatography using dichloromethane: methanol as mobile phase and the desired product eluted at around 1.8% methanol in dichloromethane to provide Compound-8 [0.170 g, 12% yield].
  • 1H NMR (DMSO, 400 MHz) δ 1.16-1.24 (m 18H), 1.47-1.51 (m, 4H), 1.57-1.62 (m, 4H), 1.70-1.75 (m, 4H), 2.30 (t, 4H), 2.38 (t, 4H), 2.57 (t, 4H), 2.80 (t, 4H), 2.96 (broad s, 8H), 3.34 (broad s, 8H), 3.97 (t, 4H), 5.86 (broad s, 4H), 6.654 (m, 4H), 7.10-7.15 (m, 4H), 7.27-7.31 (m, 4H); m/z (M+H) 1177.9.
  • While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Claims (12)

1-15. (canceled)
16. A prodrug conjugate, having the formula:
Figure US20160024011A1-20160128-C00531
Figure US20160024011A1-20160128-C00532
Figure US20160024011A1-20160128-C00533
wherein each R50, R51, R52, R53, R54 and R55 is independently selected from hydrogen, halogen, —OR10, —SR10, —NR10R11—, optionally substituted aliphatic, optionally substituted aryl or aryl or optionally substituted heterocyclyl;
alternatively, two or more R50, R51, R52, R53, R54 and R55 together form an optionally substituted ring;
each R100, R101, R102, and R103 are independently selected from absent, hydrogen, halogen, —OR10, —SR10, —NR10R11—, optionally substituted aliphatic, optionally substituted aryl or optionally substituted heterocyclyl; alternatively, two R100, and R101 together form an optionally substituted ring;
h is 3or 4;
X100 is —CH— or —N—;
C1 is a carrier moiety; and,
X2 is selected from direct bond, O, S or NR20.
17. A prodrug conjugate of claim 16, having the formula:
Figure US20160024011A1-20160128-C00534
wherein n is selected from 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30.
18. A prodrug conjugate, having the formula:
Figure US20160024011A1-20160128-C00535
wherein Cy2 is an optionally substituted heterocyclic ring; and
X5 is selected from absent, —S—, —O—, —S(O)—, —S(O)2—, —N(R10)—, —C(O)—, —C(OR10)(R11)—, —[C(R10)(R11)]v—, —O[C(R10)(R11)]v—, —O[C(R10)(R11)]vO—, —S[C(R10)(R11)]vO—, —NR12[C(R10)(R11)]vO—, —NR12[C(R10)(R11)]vS—, —S[C(R10)(R11)]v—, —C(O)[C(R10)(R11)]v—, and —C(R10)(R11)═C(R10)(R11)—; wherein v is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
C1 is a carrier moiety; and,
X2 is selected from direct bond, O, S or NR20.
19. The prodrug conjugate, having the formula:
Figure US20160024011A1-20160128-C00536
wherein A1, B1 and E1 together with the nitrogen they are attached to form a tertiary amine containing first biologically active molecule;
A2, B2 and E2 together with the nitrogen they are attached to form a tertiary amine containing second biologically active molecule;
X is a pharmaceutically acceptable counterion;
X1 is selected from O or S;
X2 is selected from direct bond, O, S or NR20 wherein R20 is selected from hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; and
C1 represents a carrier group.
20-27. (canceled)
28. The prodrug conjugate, having the formula:
Figure US20160024011A1-20160128-C00537
wherein API-1 is a biologically active moiety; and API-2 is a biologically active moiety and is the same or different from API-1; and API-3 is a biologically active moiety and is the same or different from API-1 and API-2.
29. (canceled)
30. A method for sustained delivery of a parent drug to a patient comprising administering a prodrug compound of claim 1, wherein upon administration to the patient, release of the parent drug from the prodrug is sustained.
31-33. (canceled)
34. A method of synthesizing a compound of formula I, IA or IB comprising the steps of reacting a dicarboxylic acid containing compound with thionyl chloride followed by reacting with formaldehyde or trioxane to yield chloromethyl ester which is reacted with a biologically active compound to give said compound of formula I, IA, IB.
35-80. (canceled)
US14/702,967 2010-12-23 2015-05-04 Multi-API Loading Prodrugs Abandoned US20160024011A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/702,967 US20160024011A1 (en) 2010-12-23 2015-05-04 Multi-API Loading Prodrugs
US15/864,305 US10584099B2 (en) 2010-12-23 2018-01-08 Multi-API loading prodrugs

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061427026P 2010-12-23 2010-12-23
US13/335,405 US20120202823A1 (en) 2010-12-23 2011-12-22 Multi-API Loading Prodrugs
US14/702,967 US20160024011A1 (en) 2010-12-23 2015-05-04 Multi-API Loading Prodrugs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/335,405 Continuation US20120202823A1 (en) 2010-12-23 2011-12-22 Multi-API Loading Prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/864,305 Continuation US10584099B2 (en) 2010-12-23 2018-01-08 Multi-API loading prodrugs

Publications (1)

Publication Number Publication Date
US20160024011A1 true US20160024011A1 (en) 2016-01-28

Family

ID=46314485

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/335,405 Abandoned US20120202823A1 (en) 2010-12-23 2011-12-22 Multi-API Loading Prodrugs
US14/702,967 Abandoned US20160024011A1 (en) 2010-12-23 2015-05-04 Multi-API Loading Prodrugs
US15/864,305 Active US10584099B2 (en) 2010-12-23 2018-01-08 Multi-API loading prodrugs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/335,405 Abandoned US20120202823A1 (en) 2010-12-23 2011-12-22 Multi-API Loading Prodrugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/864,305 Active US10584099B2 (en) 2010-12-23 2018-01-08 Multi-API loading prodrugs

Country Status (8)

Country Link
US (3) US20120202823A1 (en)
EP (1) EP2655314B1 (en)
JP (1) JP6013364B2 (en)
AU (1) AU2011348085B2 (en)
CA (1) CA2822447C (en)
ES (1) ES2661574T3 (en)
NZ (1) NZ612187A (en)
WO (1) WO2012088441A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190276406A1 (en) * 2009-06-25 2019-09-12 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US10898449B2 (en) 2016-12-20 2021-01-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11608320B2 (en) 2020-02-02 2023-03-21 Kuwait University Oxazolidinone hydroxamic acid derivatives
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11992559B2 (en) 2021-02-24 2024-05-28 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201812823T4 (en) 2009-11-23 2019-02-21 Cubist Pharmaceuticals Llc Lipopeptide compositions and related methods.
JO3227B1 (en) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd Piperazine-substituted benzothiophene deriveatives as antipsychotic agents
CN106596828B (en) * 2016-12-15 2018-09-25 扬子江药业集团有限公司 A kind of detection method of the methanesulfonic acid FCE-26743A in relation to substance
US20200138964A1 (en) * 2017-04-25 2020-05-07 Seikagaku Corporation Tertiary amine compound or imine compound-polymer conjugate and production method therefor
KR20200110317A (en) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 Crystal form and method for preparing the same
JP7268026B2 (en) 2017-12-05 2023-05-02 サノビオン ファーマシューティカルズ インク Non-racemic mixtures and uses thereof
CA3126348A1 (en) 2018-01-12 2020-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CA3132832A1 (en) * 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN115475253B (en) * 2021-05-31 2023-09-29 东南大学 Lapatinib-cancer cell stem inhibitor conjugate, preparation method, pharmaceutical composition and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431576B2 (en) * 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903110A (en) * 1972-04-27 1975-09-02 Gaf Corp N-(2-pyrrolidinonyl) methyl carbamate derivatives
US4260769A (en) 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
US4251443A (en) * 1979-08-02 1981-02-17 Hoffmann-La Roche Inc. Benzodiazepine derivatives
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
ATE261730T1 (en) * 1997-12-31 2004-04-15 Univ Kansas WATER-SOLUBLE MEDICINAL PRECURSORS OF TERTIARY AMINES CONTAINING MEDICATIONS AND METHOD FOR THE PRODUCTION THEREOF
US6756037B2 (en) * 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
FR2842423B1 (en) * 2002-07-18 2005-07-08 Centre Nat Rech Scient COMPOUNDS WITH ANTI-PARASITE ACTIVITY AND MEDICAMENTS CONTAINING SAME
EP1789091B1 (en) * 2004-08-26 2010-08-25 Piramal Life Sciences Limited Prodrugs containing novel bio-cleavable linkers
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
RU2470668C2 (en) * 2005-08-19 2012-12-27 Эндосайт, Инк. Conjugates of ligand and drugs
CN101415679A (en) * 2006-02-02 2009-04-22 辛塔佳有限公司 Water-solubility CC-1065 analog and composition thereof
US20100068786A1 (en) * 2008-09-16 2010-03-18 Chmielewski Jean A Methods and compositions for reversing p-glycoprotein medicated drug resistance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431576B2 (en) * 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Andrezina et al. Current Medical Research and Opinions 2006, 22 (11), 2209-2219 *
Bhosle et al. Indian Journal of Pharmaceutical Sciences 2006, May-June, p. 286-294 *
Guarino et al. Prodrugs of amides, imides and other NH-acidic compounds. In Prodrugs: Challenges and Rewards; Stella et al., Eds.; Springer: New York, 2007; Part 1, Chapter 3.4, p. 133-187 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190276406A1 (en) * 2009-06-25 2019-09-12 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US10822306B2 (en) * 2009-06-25 2020-11-03 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US10898449B2 (en) 2016-12-20 2021-01-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US10980753B2 (en) 2016-12-20 2021-04-20 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11608320B2 (en) 2020-02-02 2023-03-21 Kuwait University Oxazolidinone hydroxamic acid derivatives
US11992559B2 (en) 2021-02-24 2024-05-28 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same

Also Published As

Publication number Publication date
WO2012088441A1 (en) 2012-06-28
JP2014508129A (en) 2014-04-03
CA2822447A1 (en) 2012-06-28
JP6013364B2 (en) 2016-10-25
US10584099B2 (en) 2020-03-10
CA2822447C (en) 2018-05-01
EP2655314A4 (en) 2014-06-04
EP2655314A1 (en) 2013-10-30
EP2655314B1 (en) 2018-02-07
NZ612187A (en) 2015-07-31
US20180194732A1 (en) 2018-07-12
US20120202823A1 (en) 2012-08-09
ES2661574T3 (en) 2018-04-02
AU2011348085B2 (en) 2016-12-08
AU2011348085A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
US10584099B2 (en) Multi-API loading prodrugs
US11225490B2 (en) Prodrugs of secondary amine compounds
US9670200B2 (en) Quaternary ammonium salt prodrugs
US9585965B2 (en) Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9580417B2 (en) Prodrugs of heteraromatic compounds
NZ623861B2 (en) Prodrugs of secondary amine compounds

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION